WO2010128309A1 - Combination therapy comprising a taxane and a sigma receptor ligand sauch as rimcazole - Google Patents
Combination therapy comprising a taxane and a sigma receptor ligand sauch as rimcazole Download PDFInfo
- Publication number
- WO2010128309A1 WO2010128309A1 PCT/GB2010/000926 GB2010000926W WO2010128309A1 WO 2010128309 A1 WO2010128309 A1 WO 2010128309A1 GB 2010000926 W GB2010000926 W GB 2010000926W WO 2010128309 A1 WO2010128309 A1 WO 2010128309A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- receptor ligand
- pharmaceutically acceptable
- sigma receptor
- stabilising agent
- acceptable derivative
- Prior art date
Links
- 239000003982 sigma receptor ligand Substances 0.000 title claims abstract description 127
- GUDVQJXODNJRIJ-CALCHBBNSA-N 9-[3-[(3S,5R)-3,5-dimethyl-1-piperazinyl]propyl]carbazole Chemical compound C1[C@@H](C)N[C@@H](C)CN1CCCN1C2=CC=CC=C2C2=CC=CC=C21 GUDVQJXODNJRIJ-CALCHBBNSA-N 0.000 title claims description 88
- 229950004933 rimcazole Drugs 0.000 title claims description 85
- 229940123237 Taxane Drugs 0.000 title claims description 54
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 title claims description 51
- 238000002648 combination therapy Methods 0.000 title description 3
- 102000029749 Microtubule Human genes 0.000 claims abstract description 140
- 108091022875 Microtubule Proteins 0.000 claims abstract description 140
- 210000004688 microtubule Anatomy 0.000 claims abstract description 140
- 239000003381 stabilizer Substances 0.000 claims abstract description 129
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 100
- 201000011510 cancer Diseases 0.000 claims abstract description 55
- 229960001592 paclitaxel Drugs 0.000 claims description 85
- 239000000203 mixture Substances 0.000 claims description 79
- 229930012538 Paclitaxel Natural products 0.000 claims description 77
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 76
- 238000011282 treatment Methods 0.000 claims description 66
- 238000000034 method Methods 0.000 claims description 60
- 238000009472 formulation Methods 0.000 claims description 40
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 32
- 239000003795 chemical substances by application Substances 0.000 claims description 27
- 150000003839 salts Chemical class 0.000 claims description 27
- -1 use Substances 0.000 claims description 25
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims description 16
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 16
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 claims description 16
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 14
- 206010006187 Breast cancer Diseases 0.000 claims description 13
- 208000026310 Breast neoplasm Diseases 0.000 claims description 13
- 239000003446 ligand Substances 0.000 claims description 13
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 11
- 229960003668 docetaxel Drugs 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 229960005500 DHA-paclitaxel Drugs 0.000 claims description 9
- LRCZQSDQZJBHAF-PUBGEWHCSA-N dha-paclitaxel Chemical compound N([C@H]([C@@H](OC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC)C(=O)O[C@@H]1C(=C2[C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]3[C@H](OC(=O)C=3C=CC=CC=3)[C@](C2(C)C)(O)C1)OC(C)=O)C)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 LRCZQSDQZJBHAF-PUBGEWHCSA-N 0.000 claims description 9
- UUKPIWYXWLJPJF-UHFFFAOYSA-N 2-(2-adamantyl)-1-(4-iodophenyl)guanidine Chemical compound C1C2CC(C3)CC1CC3C2N=C(N)NC1=CC=C(I)C=C1 UUKPIWYXWLJPJF-UHFFFAOYSA-N 0.000 claims description 8
- WNZBBTJFOIOEMP-UHFFFAOYSA-N Hydroxyhaloperidol Chemical compound C=1C=C(F)C=CC=1C(O)CCCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 WNZBBTJFOIOEMP-UHFFFAOYSA-N 0.000 claims description 8
- 229960003878 haloperidol Drugs 0.000 claims description 8
- 238000001990 intravenous administration Methods 0.000 claims description 7
- 238000002560 therapeutic procedure Methods 0.000 claims description 7
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 6
- 210000000481 breast Anatomy 0.000 claims description 6
- 230000012010 growth Effects 0.000 claims description 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 6
- 230000002611 ovarian Effects 0.000 claims description 5
- 231100000419 toxicity Toxicity 0.000 claims description 5
- 230000001988 toxicity Effects 0.000 claims description 5
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 description 48
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 19
- 239000008194 pharmaceutical composition Substances 0.000 description 15
- 239000000651 prodrug Substances 0.000 description 15
- 229940002612 prodrug Drugs 0.000 description 15
- 230000004614 tumor growth Effects 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 239000000843 powder Substances 0.000 description 13
- 239000007787 solid Substances 0.000 description 10
- 230000002354 daily effect Effects 0.000 description 9
- 239000002552 dosage form Substances 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 239000007921 spray Substances 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- 208000012766 Growth delay Diseases 0.000 description 8
- 239000000839 emulsion Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 229920000642 polymer Polymers 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 239000008101 lactose Substances 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000003111 delayed effect Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 108010085082 sigma receptors Proteins 0.000 description 6
- 239000012453 solvate Substances 0.000 description 6
- ZWHRZGHGYMUSRM-VWDRLOGHSA-N 9-[3-[(3r,5s)-3,5-dimethylpiperazin-1-yl]propyl]carbazole;hydron;dichloride Chemical compound Cl.Cl.C1[C@@H](C)N[C@@H](C)CN1CCCN1C2=CC=CC=C2C2=CC=CC=C21 ZWHRZGHGYMUSRM-VWDRLOGHSA-N 0.000 description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 229930195725 Mannitol Natural products 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000008485 antagonism Effects 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 230000022131 cell cycle Effects 0.000 description 5
- 238000011284 combination treatment Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 238000007918 intramuscular administration Methods 0.000 description 5
- 239000000594 mannitol Substances 0.000 description 5
- 235000010355 mannitol Nutrition 0.000 description 5
- 229920000609 methyl cellulose Polymers 0.000 description 5
- 239000001923 methylcellulose Substances 0.000 description 5
- 235000010981 methylcellulose Nutrition 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000000600 sorbitol Substances 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 4
- OPNUROKCUBTKLF-UHFFFAOYSA-N 1,2-bis(2-methylphenyl)guanidine Chemical compound CC1=CC=CC=C1N\C(N)=N\C1=CC=CC=C1C OPNUROKCUBTKLF-UHFFFAOYSA-N 0.000 description 4
- 229920000858 Cyclodextrin Polymers 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000025084 cell cycle arrest Effects 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 229920006237 degradable polymer Polymers 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000007902 hard capsule Substances 0.000 description 4
- 150000004677 hydrates Chemical class 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 238000010902 jet-milling Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 206010033675 panniculitis Diseases 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 229920000747 poly(lactic acid) Polymers 0.000 description 4
- 239000003380 propellant Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000007901 soft capsule Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 210000004304 subcutaneous tissue Anatomy 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 230000002459 sustained effect Effects 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000007937 lozenge Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 239000008389 polyethoxylated castor oil Substances 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- PJRSUKFWFKUDTH-JWDJOUOUSA-N (2s)-6-amino-2-[[2-[[(2s)-2-[[(2s,3s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[(2-aminoacetyl)amino]-4-methylsulfanylbutanoyl]amino]propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]propanoyl]amino]acetyl]amino]propanoyl Chemical compound CSCC[C@H](NC(=O)CN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(N)=O PJRSUKFWFKUDTH-JWDJOUOUSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 2
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 2
- SUIZRDJCBVPASY-UHFFFAOYSA-N 1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine Chemical compound C1CN(C)CCN1CCC1=CC=C(Cl)C(Cl)=C1 SUIZRDJCBVPASY-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 229920002732 Polyanhydride Polymers 0.000 description 2
- 229920000331 Polyhydroxybutyrate Polymers 0.000 description 2
- 229920001710 Polyorthoester Polymers 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000004147 Sorbitan trioleate Substances 0.000 description 2
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 208000002847 Surgical Wound Diseases 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 239000000227 bioadhesive Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000015111 chews Nutrition 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 229940097362 cyclodextrins Drugs 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229940126534 drug product Drugs 0.000 description 2
- 229940112141 dry powder inhaler Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 238000007919 intrasynovial administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 238000007915 intraurethral administration Methods 0.000 description 2
- 238000007914 intraventricular administration Methods 0.000 description 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000005772 leucine Nutrition 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 239000003595 mist Substances 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- 230000003232 mucoadhesive effect Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 239000007923 nasal drop Substances 0.000 description 2
- 229940100662 nasal drops Drugs 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000003182 parenteral nutrition solution Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 108010021753 peptide-Gly-Leu-amide Proteins 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 239000005015 poly(hydroxybutyrate) Substances 0.000 description 2
- 239000004632 polycaprolactone Substances 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 229920000193 polymethacrylate Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 235000019337 sorbitan trioleate Nutrition 0.000 description 2
- 229960000391 sorbitan trioleate Drugs 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000009747 swallowing Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- MOXLMXQSFOOZDO-WIRZRDCJSA-N (1S,9R)-10-(cyclopropylmethyl)-12-ethyl-4-hydroxy-13-methyl-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-8-one Chemical compound CCC([C@H]1C(C)[C@@H]2C(C3=CC=C(O)C=C31)=O)CN2CC1CC1 MOXLMXQSFOOZDO-WIRZRDCJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- ZXUYYZPJUGQHLQ-UHFFFAOYSA-N 1-(4-fluorophenyl)-4-[4-(5-fluoro-2-pyrimidinyl)-1-piperazinyl]-1-butanol Chemical compound C=1C=C(F)C=CC=1C(O)CCCN(CC1)CCN1C1=NC=C(F)C=N1 ZXUYYZPJUGQHLQ-UHFFFAOYSA-N 0.000 description 1
- SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 description 1
- LLSKXGRDUPMXLC-UHFFFAOYSA-N 1-phenylpiperidine Chemical class C1CCCCN1C1=CC=CC=C1 LLSKXGRDUPMXLC-UHFFFAOYSA-N 0.000 description 1
- ZESRJSPZRDMNHY-YFWFAHHUSA-N 11-deoxycorticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 ZESRJSPZRDMNHY-YFWFAHHUSA-N 0.000 description 1
- DCYGAPKNVCQNOE-UHFFFAOYSA-N 2,2,2-triphenylacetic acid Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)O)C1=CC=CC=C1 DCYGAPKNVCQNOE-UHFFFAOYSA-N 0.000 description 1
- KYQWKVHYBNLXGX-UHFFFAOYSA-N 2-[4-[4-(2,4-dioxo-1-thia-3-azaspiro[4.4]nonan-3-yl)butyl]piperazin-1-yl]pyridine-3-carbonitrile;hydrochloride Chemical compound Cl.O=C1N(CCCCN2CCN(CC2)C=2C(=CC=CN=2)C#N)C(=O)SC21CCCC2 KYQWKVHYBNLXGX-UHFFFAOYSA-N 0.000 description 1
- WBJWXIQDBDZMAW-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carbonyl chloride Chemical compound C1=CC=CC2=C(C(Cl)=O)C(O)=CC=C21 WBJWXIQDBDZMAW-UHFFFAOYSA-N 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-N 3-Hydroxy-2-naphthoate Chemical compound C1=CC=C2C=C(O)C(C(=O)O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-N 0.000 description 1
- HTSNFXAICLXZMA-ZDUSSCGKSA-N 3-[(3r)-1-propylpiperidin-3-yl]phenol Chemical compound C1N(CCC)CCC[C@@H]1C1=CC=CC(O)=C1 HTSNFXAICLXZMA-ZDUSSCGKSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- GUJRSXAPGDDABA-NSHDSACASA-N 3-bromo-N-[[(2S)-1-ethyl-2-pyrrolidinyl]methyl]-2,6-dimethoxybenzamide Chemical compound CCN1CCC[C@H]1CNC(=O)C1=C(OC)C=CC(Br)=C1OC GUJRSXAPGDDABA-NSHDSACASA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical group N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- XRHGYUZYPHTUJZ-UHFFFAOYSA-N 4-chlorobenzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1 XRHGYUZYPHTUJZ-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- ZFZPJDFBJFHYIV-UHFFFAOYSA-N 8-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-8-azaspiro[4.5]decane-7,9-dione Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2C3=CC=CC=C3SN=2)C(=O)CC21CCCC2 ZFZPJDFBJFHYIV-UHFFFAOYSA-N 0.000 description 1
- GUDVQJXODNJRIJ-UHFFFAOYSA-N 9-[3-(3,5-dimethyl-1-piperazinyl)propyl]carbazole Chemical compound C1C(C)NC(C)CN1CCCN1C2=CC=CC=C2C2=CC=CC=C21 GUDVQJXODNJRIJ-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 1
- 230000004668 G2/M phase Effects 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- KLPWJLBORRMFGK-UHFFFAOYSA-N Molindone Chemical compound O=C1C=2C(CC)=C(C)NC=2CCC1CN1CCOCC1 KLPWJLBORRMFGK-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 239000006057 Non-nutritive feed additive Substances 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100028656 Sigma non-opioid intracellular receptor 1 Human genes 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 241001116498 Taxus baccata Species 0.000 description 1
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- WNTYBHLDCKXEOT-UHFFFAOYSA-N acetophenazine Chemical compound C12=CC(C(=O)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(CCO)CC1 WNTYBHLDCKXEOT-UHFFFAOYSA-N 0.000 description 1
- 229960000276 acetophenazine Drugs 0.000 description 1
- 239000000980 acid dye Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- PYHXGXCGESYPCW-UHFFFAOYSA-N alpha-phenylbenzeneacetic acid Natural products C=1C=CC=CC=1C(C(=O)O)C1=CC=CC=C1 PYHXGXCGESYPCW-UHFFFAOYSA-N 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 150000003939 benzylamines Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 229950006479 butaclamol Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- ZESRJSPZRDMNHY-UHFFFAOYSA-N de-oxy corticosterone Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 ZESRJSPZRDMNHY-UHFFFAOYSA-N 0.000 description 1
- 239000000551 dentifrice Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960003654 desoxycortone Drugs 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- OZYUPQUCAUTOBP-QRQLOZEOSA-N dextrallorphan Chemical compound C([C@@H]12)CCC[C@]11CCN(CC=C)[C@@H]2CC2=CC=C(O)C=C21 OZYUPQUCAUTOBP-QRQLOZEOSA-N 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 125000000567 diterpene group Chemical group 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 229960002690 fluphenazine Drugs 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960004938 molindone Drugs 0.000 description 1
- INAXVFBXDYWQFN-XHSDSOJGSA-N morphinan Chemical class C1C2=CC=CC=C2[C@]23CCCC[C@H]3[C@@H]1NCC2 INAXVFBXDYWQFN-XHSDSOJGSA-N 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- LGQCVMYAEFTEFN-UHFFFAOYSA-N n-allylnormetazocine Chemical compound C1C2=CC=C(O)C=C2C2(C)C(C)C1N(CC=C)CC2 LGQCVMYAEFTEFN-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229950006344 nocodazole Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 description 1
- 229960003634 pimozide Drugs 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
- 229960001237 podophyllotoxin Drugs 0.000 description 1
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960003448 remoxipride Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 108010080097 sigma-1 receptor Proteins 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960002784 thioridazine Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229950004554 tiospirone Drugs 0.000 description 1
- LGQCVMYAEFTEFN-DQYPLSBCSA-N tocris-1079 Chemical compound C1C2=CC=C(O)C=C2[C@]2(C)[C@H](C)[C@H]1N(CC=C)CC2 LGQCVMYAEFTEFN-DQYPLSBCSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- XSCGXQMFQXDFCW-UHFFFAOYSA-N triflupromazine Chemical compound C1=C(C(F)(F)F)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 XSCGXQMFQXDFCW-UHFFFAOYSA-N 0.000 description 1
- 229960003904 triflupromazine Drugs 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 231100000747 viability assay Toxicity 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the invention relates to compounds which, when used in combination, are surprisingly active against cancer.
- the invention also relates to methods of using these compounds, and compositions and kits that comprise these compounds.
- Taxanes a class of diterpenes originally derived from yew trees, are known to be effective in treating various cancers. They have been shown to promote the polymerisation of microtubules and thereby increase microtubule stability. The two taxanes currently licensed for use in humans are paclitaxel (TaxolTM) and docetaxel (TaxotereTM). Paclitaxel binds to GDP-tubulin and stops microtubule depolymerisation. This results in highly stabilised microtubules, thereby preventing normal cell function.
- Paclitaxel is effective in the treatment of metastatic breast cancer (Dombernowsky et al., 1995 Seminars in Oncology 22(6): 13-17) and in a range of other solid tumours (Kaye 1995 Seminars in Oncology 22(2): 30-33). et al
- Rimcazole is a sigma receptor ligand which has been shown to be effective in inhibiting the growth of tumours in preclinical tumour xenografts models (Spruce et al., 2004 Cancer Research 64: 4875-4886). Mechanistic studies (WO 00/00599) have shown that Rimcazole may synergise with agents such as colchicine, nocodazole, podophyllotoxin and vinblastine to depolymerise or destabilise microtubules.
- the treatment of cancer using a taxane or a sigma receptor ligand has a number of problems. Administration of these agents has been associated with toxicity, leading to the use of sub-optimal doses and, in some cases, low efficacy. Furthermore, cancer therapy using these compounds in isolation can fail because cancers become resistant to the compound by mutation. In addition, further compounds are required in order to improve the selectivity of the treatment for different cancers, thereby allowing improved efficacy and/or reduced toxicity.
- a microtubule stabilising agent such as a taxane
- a sigma receptor ligand such as Rimcazole
- Rimcazole has been shown to be co-operative with microtubule destabilising agents in it's anti-tumour action (see WO 00/00599) whilst the taxanes are known stabilisers of microtubules. Given that Rimcazole is co-operative with microtubule destabilising agents, the skilled person would not have expected co-operation or synergy between Rimcazole and microtubule stabilising agents. Indeed, in vitro studies suggested that Rimcazole and paclitaxel have no co-operativity or synergy.
- microtubule stabilising agents and sigma receptor ligands can be used in combination in treating cancer. Furthermore, the inventors have demonstrated that the efficacy of these compounds in combination is greater than their combined separate efficacies, i.e. the combination has an unexpected synergistic effect.
- the present invention provides a microtubule stabilising agent selected from: a taxane, or a pharmaceutically acceptable derivative thereof, and a sigma receptor ligand, for use in treating cancer, wherein said treatment involves administering said microtubule stabilising agent and said sigma receptor ligand separately, sequentially or simultaneously.
- the invention provides a microtubule stabilising agent selected from a taxane, or a pharmaceutically acceptable derivative thereof, for use in treating cancer in a patient, wherein the patient has been previously treated, or is currently being treated with, a sigma receptor ligand.
- the invention provides a microtubule stabilising agent selected from: a taxane, or a pharmaceutically acceptable derivative thereof, for use in a method of treating cancer in a patient, wherein the microtubule stabilising agent is prepared for simultaneous, separate or sequential administration with a sigma receptor ligand.
- the invention provides a sigma receptor ligand, for use in treating cancer in a patient, wherein the patient has been previously treated, or is currently being treated with a microtubule stabilising agent selected from: a taxane, or a pharmaceutically acceptable derivative thereof.
- the invention provides a sigma receptor ligand for use in treating cancer in a patient, wherein the sigma receptor ligand is prepared for simultaneous, separate or sequential administration with a microtubule stabilising agent selected from: a taxane, or a pharmaceutically acceptable derivative thereof.
- the invention provides the use of a microtubule stabilising agent selected from: a taxane, or a pharmaceutically acceptable derivative thereof, and a sigma receptor ligand, in a method of manufacturing a medicament for the treatment of cancer.
- the invention provides the use of a microtubule stabilising agent selected from: a taxane, or a pharmaceutically acceptable derivative thereof, in a method of manufacturing a medicament for the treatment of cancer, wherein said treatment comprises the administration of a sigma receptor ligand .
- the invention provides the use of a sigma receptor ligand in a method of manufacturing a medicament for the treatment of cancer, wherein said treatment comprises the administration of a microtubule stabilising agent selected from: a taxane, or a pharmaceutically acceptable derivative thereof.
- the invention provides the use of a microtubule stabilising agent selected from: a taxane, or a pharmaceutically acceptable derivative thereof, in a method of manufacturing a medicament for the treatment of a patient with cancer, wherein said patient has been previously treated, or is currently being treated with a sigma receptor ligand .
- the invention provides the use of a sigma receptor ligand in a method of manufacturing a medicament for the treatment of a patient with cancer, wherein said patient has been previously treated, or is currently being treated with a microtubule stabilising agent selected from: a taxane, or a pharmaceutically acceptable derivative thereof.
- the invention provides a composition comprising a microtubule stabilising agent selected from: a taxane, or a pharmaceutically acceptable derivative thereof, and a sigma receptor ligand.
- the invention provides a kit comprising a microtubule stabilising agent selected from: a taxane, or a pharmaceutically acceptable derivative thereof, and a sigma receptor ligand.
- a microtubule stabilising agent selected from: a taxane, or a pharmaceutically acceptable derivative thereof, and a sigma receptor ligand.
- the invention provides the use of any of the above compositions in a method of treating cancer, wherein said method comprises the separate, sequential or simultaneous administration of a microtubule stabilising agent selected from: a taxane, or a pharmaceutically acceptable derivative thereof, and a sigma receptor ligand.
- a microtubule stabilising agent selected from: a taxane, or a pharmaceutically acceptable derivative thereof, and a sigma receptor ligand.
- the invention provides a method of treatment of cancer in a patient in need thereof, wherein said method comprises administering to said patient a therapeutically effective amount of: a microtubule stabilising agent selected from: a taxane, or a pharmaceutically acceptable derivative thereof, and therapeutically effective amount of a sigma receptor ligand , wherein said a microtubule stabilising agent and said sigma receptor ligand are administered separately, sequentially or simultaneously.
- a microtubule stabilising agent selected from: a taxane, or a pharmaceutically acceptable derivative thereof
- a sigma receptor ligand therapeutically effective amount of a sigma receptor ligand
- the invention provides a method of treatment of cancer in a patient in need thereof, wherein said method comprises administering to said patient a therapeutically effective amount of a microtubule stabilising agent selected from: a taxane, or a pharmaceutically acceptable derivative thereof, wherein a therapeutically effective amount of a sigma receptor ligand has been previously administered to said patient.
- a microtubule stabilising agent selected from: a taxane, or a pharmaceutically acceptable derivative thereof, wherein a therapeutically effective amount of a sigma receptor ligand has been previously administered to said patient.
- the invention provides a method of treatment of cancer in a patient in need thereof, wherein said method comprises administering to said patient a therapeutically effective amount of a sigma receptor ligand , wherein a therapeutically effective amount of a microtubule stabilising agent selected from: a taxane, or a pharmaceutically acceptable derivative thereof has been previously administered to said patient.
- the invention provides a method of reducing the toxicity of a microtubule stabilising agent selected from: a taxane, or a pharmaceutically acceptable derivative thereof, by administering said microtubule stabilising agent in combination with a sigma receptor ligand.
- the invention provides a method of delaying the growth of a tumour by administering a microtubule stabilising agent selected from: a taxane, or a pharmaceutically acceptable derivative thereof in combination with a sigma receptor ligand.
- a microtubule stabilising agent selected from: a taxane, or a pharmaceutically acceptable derivative thereof in combination with a sigma receptor ligand.
- the invention provides a method of prolonging the life span of a patient with cancer, by administrating a microtubule stabilising agent selected from: a taxane, or a pharmaceutically acceptable derivative thereof in combination with a sigma receptor ligand.
- a microtubule stabilising agent selected from: a taxane, or a pharmaceutically acceptable derivative thereof in combination with a sigma receptor ligand.
- the invention provides a method of treating breast cancer in a patient in need thereof, wherein said method comprises administering to said patient a therapeutically effective amount of paclitaxel, and a therapeutically effective amount of Rimcazole wherein said administration is separate, sequential or simultaneous.
- the invention provides a method of treatment of cancer in a patient in need thereof, wherein said method comprises administering to said patient a therapeutically effective amount of A and a therapeutically effective amount of B, wherein A is a taxane, or a pharmaceutically acceptable derivative thereof, and B is a sigma receptor ligand , wherein A and B are administered separately, sequentially or simultaneously.
- microtubule stabilising agent The microtubule stabilising agent
- a microtubule stabilising agent is an agent that increases the stability of microtubules, an effect which can be observed in the microtubule stabilisation assays discussed in Shelanski et al. PNAS 70, 3, p765, 1973. Shelanski et al. describes how microtubule stabilisation may be measured by light scattering, preferably in combination with an electron microscope, and / or by using centrifugation.
- microtubule stabilising agent is a taxane or a pharmaceutically derivative thereof.
- Methods of synthesising microtubule stabilising agents are described in U.S. 4,924,011, U.S. 4,924,012 and U.S. 5,175,315.
- pharmaceutically acceptable derivative includes pharmaceutically acceptable salts, solvates, hydrates, metabolites, prodrugs and isomers.
- the microtubule stabilising agent may be paclitaxel (taxolTM), docetaxel (taxotereTM), DHA-paclitaxel (taxoprexinTM), polyglutimate- taxol (OPAXIOTM), or a prodrug, pharmaceutically acceptable salt, solvate, hydrate, derivative, isomer or metabolite thereof.
- the microtubule stabilising agent is preferably paclitaxel (taxolTM).
- the microtubule stabilising agent can be formulated using any of the techniques known in the art. For example, it can be provided as a solid tablet, power, solution, dispersion, emulsion, or suspension. It can be formulated in liposomes, in polyethoxylated castor oil, in ethanol, bound to albumin and / or in tween 80TM.
- the agent is paclitaxel and it is formulated with polyethoxylated castor oil and / or ethanol.
- the agent is docetaxel and it is formulated with albumin in saline solution.
- Pharmaceutically acceptable salts of the taxane may include those of inorganic acids, for example, hydrohalic acids such as hydrochloric acid, hydrobromic acid or hydroiodic acid, nitric acid, sulfuric acid, phosphoric acid; and organic acids, for example aliphatic monocarboxylic acids such as formic acid, acetic acid, propionic acid and butyric acid, aliphatic hydroxy acids such as lactic acid, citric acid, tartaric acid or malic acid, dicarboxylic acids such as maleic acid or succinic acid, aromatic carboxylic acids such as benzoic acid, p-chlorobenzoic acid, diphenylacetic acid or triphenylacetic acid, aromatic hydroxy acids such as o-hydroxybenzoic acid, p-hydroxybenzoic acid, 1- hydroxynaphthalene-2-carboxylic acid or 3-hydroxynaphthalene-2-carboxylic acid, and sulfonic acids such as methanesulfonic acid or benzene
- the microtubule stabilising agent contains acidic, e.g. carboxyl, groups, it may also be capable of forming salts with bases, in particular pharmaceutically acceptable bases such as those well known in the art; suitable such salts include metal salts, particularly alkali metal or alkaline earth metal salts such as sodium, potassium, magnesium or calcium salts, or salts with ammonia or pharmaceutically acceptable organic amines or heterocyclic bases such as ethanolamines, benzylamines or pyridine. These salts may be prepared by known salt- forming procedures.
- the microtubule stabilising agent may be in the form of a prodrug.
- Said prodrug may be selected from the group consisting of esters, amides and hydrates.
- pro-drug is also meant to include any covalently bonded carrier which releases the active compound of the invention in vivo when such prodrug is administered to a subject.
- Pro-drugs of a microtubule stabilising agent of the invention may be prepared by modifying functional groups present in the compound of the invention in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compound of the invention.
- optically active compounds used in the invention embrace all individual optically active R and S isomers as well as mixtures, e.g. racemic or diastereomeric mixtures, thereof.
- the present invention includes pharmaceutically acceptable isotopically-labeled versions of the microtubule stabilising agents mentioned herein.
- Said pharmaceutically acceptable isotopically-labeled versions of the compounds are compounds wherein one or more atoms from a compound mentioned herein are replaced by atoms having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
- isotopes suitable for inclusion in the compounds of the invention comprises isotopes of hydrogen, such as 2 H and 3 H, carbon, such as 11 C, 13 C and 14 C, chlorine, such as 36 Cl, fluorine, such as 18 F, iodine, such as 123 I and 123 I, nitrogen, such as 13 N and 15 N, oxygen, such as 15 O, 17 O and 18 O, phosphorus, such as 32 P, and sulphur, such as 33 S.
- hydrogen such as 2 H and 3 H
- carbon such as 11 C, 13 C and 14 C
- chlorine such as 36 Cl
- fluorine such as 18 F
- iodine such as 123 I and 123 I
- nitrogen such as 13 N and 15 N
- oxygen such as 15 O, 17 O and 18 O
- phosphorus such as 32 P
- sulphur such as 33 S.
- substitution with heavier isotopes such as deuterium, i.e. 2 H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances.
- Isotopically-labelled compounds mentioned herein can generally be prepared by the methods used in the art, for example, by modifying a known method for making a compound disclosed herein by using isotopically-labelled reagents.
- a sigma receptor ligand is a ligand that binds to the sigma receptor, an effect which can be observed in a sigma receptor binding assay (Vilner et al. Cancer Res 55(2):408-413, 1995 (see page 409, column 1, second paragraph).
- the binding of a putative sigma ligand to sites on sigma receptors, especially sigma 1 receptors can be measured by comparison to the prototypic sigma ligands such as (+)-pentazocine and 1 ,3-di-o-tolylguanidine (DTG).
- Radio- or chemically- labelled prototype sigma ligands are allowed to bind to sigma receptors in a cell preparation. The amount of labelled prototype sigma ligands displaced by the putative ligand is measured and used to calculate the affinity of the putative ligand for the sigma receptor.
- a putative sigma ligand has an affinity of less than lO ⁇ M, it is considered to be a sigma receptor ligand.
- Suitable sigma receptor ligands for use in the present invention include those listed in list 1 below:
- Rimcazole Rimcazole dihydrochloride, Rimcazole hydrochloride, haloperidol, reduced haloperidol, IPAG (l -(4-iodophenyl)-3-(2-adamantyl)guanidine), BD- 1047 (N(-)[2-(3,4- dichlorophenyl)ethyl]-N-methyl-2-(dimethylamino)ethylamine), BD-1063 (l (-)[2-(3,4- dichlorophenyl)ethyl]-4-methylpiperazine), (+)-SKF- 10047 ((+)-N-allyl normetazocine), (+)-benzomorphans including (+)-petazocine and (+)-ethylketocyclazocine, (+)-morphinans including dextrallorphan, cis isomers of U50488 and analogues, arylcyclohexamines including PCP, N,N'-diryl-
- suitable sigma receptor ligands for use in the present invention are selected from list 2 below.
- any one of the members of list 1 may be used, intended for use or formulated with paclitaxel.
- any one of the members of list 1 may be used, intended for use or formulated with docetaxel.
- any one of the members of list 1 may be used, intended for use or formulated with DHA-paclitaxel.
- any one of the members of list 1 may be used, intended for use or formulated with polyglutimate-taxol.
- any one of the members of list 2 may be used, intended for use or formulated with paclitaxel.
- any one of the members of list 2 may be used, intended for use or formulated with docetaxel.
- any one of the members of list 2 may be used, intended for use or formulated with DHA-paclitaxel.
- any one of the members of list 2 may be used, intended for use or formulated with polyglutimate-taxol.
- the sigma receptor ligand may be Rimcazole, or a pharmaceutically acceptable derivative thereof.
- the sigma receptor ligand may be specifically Rimcazole or a pharmaceutically acceptable salt thereof. In any of the above aspects of the invention, the sigma receptor ligand may be Rimcazole.
- pharmaceutically acceptable derivative includes pharmaceutically acceptable salts, solvates, hydrates, metabolites, prodrugs and isomers.
- Rimcazole 9-[3-[3,5-dimethylpiperazin-l-yl]propyl]carbazole (BW 234U) is known as Rimcazole.
- Methods of synthesising Rimcazole are known in the art, e.g. as described in EP 0 012 208, US 5,955,459 and WO01/74359.
- compositions when applied to Rimcazole includes pharmaceutically acceptable salts, solvates, amides and prodrugs of Rimcazole.
- Rimcazole has two stereogenic centres at the 3 and 5 positions of the piperazinyl ring and, as used herein, the term "Rimcazole” includes stereoisomers of Rimcazole.
- the stereoisomer of Rimcazole is the (3S,5R) isomer, i.e. 9-[3-[(3S,5R)-3,5- dimethylpiperazin-l-yl]propyl]carbazole having the structural formula I:
- Suitable pharmaceutically acceptable salts include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.
- a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.
- the pharmaceutically acceptable salt is a hydrochloride salt of Rimcazole, typically the dihydrochloride salt (Rimcazole dihydrochloride).
- Rimcazole dihydrochloride typically the dihydrochloride salt (Rimcazole dihydrochloride).
- the salt is Rimcazole dihydrochloride, which is of structural formula II:
- pharmaceutically acceptable solvate includes hydrates or solvates formed with common organic solvents.
- the hydrate is Rimcazole dihydrochloride monohydrate.
- the Rimcazole or a pharmaceutically acceptable derivative thereof may have one or more polymorph or amorphous crystalline forms and are also included in the invention.
- pharmaceutically acceptable amide includes compounds formed by the reaction of Rimcazole with a carboxylic acid, e.g. a Cl -6 carboxylic acid.
- a carboxylic acid e.g. a Cl -6 carboxylic acid.
- the use of pharmaceutically acceptable amides as prodrugs is discussed, for example, in "The Theory and Practice of Industrial Pharmacy", 2nd Edition, Lachman, Lieberman & Kanig, 1976.
- prodrug means a pharmaceutically acceptable form of a functional derivative of Rimcazole (or a salt thereof), wherein the prodrug may be: 1) a relatively active precursor which converts in vivo to an active prodrug component; 2) a relatively inactive precursor which converts in vivo to an active prodrug component; or 3) a relatively less active component of the compound that contributes to therapeutic biological activity after becoming available in vivo.
- suitable prodrug derivatives are described in, for example, EP 0 012 208.
- the present invention is useful in the treatment cancer.
- the cancer may be cancer of the bladder, breast (female and / or male), kidney, lung, pancreas, prostate, skin, thyroid, liver, oesophagus, stomach, ovary, brain and/or central nervous system, uterus, bone and/or connective tissue and, in addition, the cancer may be leukaemia, melanoma, non-Hodgkin Lymphoma cervical, colorectal, myeloma, mesothelioma, oral, uterine, non-small cell lung carcinoma and Kaposi's sarcoma.
- the cancer may be specifically any one of ovarian, breast, non-small cell lung carcinoma or Kaposi's sarcoma.
- the cancer may be specifically breast cancer.
- the cancer may be hormone insensitive breast cancer.
- Hormone insensitive breast cancer may be more particularly defined as breast cancer which does not respond to hormone based breast cancer treatments.
- the compounds of the present invention may be useful as both prophylactic and therapeutic treatments for cancer.
- X may be being administered intravenously.
- the amount of any compound or composition mentioned herein (or a pharmaceutically acceptable derivative thereof) administered as part of the invention should be a therapeutically effective amount where the any compound or composition mentioned herein is used for the treatment of a disease or condition, and a prophylactically effective amount where the compound or derivative is used for the prevention of a disease or condition.
- treatment includes prophylactic treatment.
- a “patient” means an animal, e.g. a mammal, typically a human, in need of treatment.
- terapéuticaally effective amount refers to the amount of any compound or composition mentioned herein (or a pharmaceutically acceptable derivative thereof) needed to treat or ameliorate a targeted disease or condition.
- prophylactically effective amount used herein refers to the amount of compound needed to prevent a targeted disease or condition.
- the exact dosage will generally be dependent on the patient's status at the time of administration. Factors that may be taken into consideration when determining dosage include the severity of the disease state in the patient, the general health of the patient, the age, weight, gender, diet, time and frequency of administration, drug combinations, reaction sensitivities and the patient's tolerance or response to therapy. The precise amount can be determined by routine experimentation, but may ultimately lie with the judgement of the clinician.
- the present invention relates to taxol and Rimcazole or a pharmaceutically acceptable derivative thereof for treating cancer, in particular breast cancer.
- the microtubule stabilising agent and the sigma receptor ligand are administered to the patient at the same time.
- the microtubule stabilising agent may be administered to the patient at exactly the same time as the sigma receptor ligand ⁇ i.e. the two compounds are administered simultaneously).
- the microtubule stabilising agent may be administered to the patient at approximately the same time as the sigma receptor ligand ⁇ i.e. the two therapies are not administered at precisely the same time ), e.g. during the same visit to a physician or healthcare professional.
- the microtubule stabilising agent and the sigma receptor ligand are not administered to the patient at the same time, but are administered sequentially (consecutively) in either order.
- the methods of the present invention may comprise administering a microtubule stabilising agent to the patient before administering a sigma receptor ligand.
- the methods may comprise administering a microtubule stabilising agent to the patient after administering a sigma receptor ligand.
- the compounds may be administered in such a way that both compounds exert a therapeutic effect on the patient at the same time ⁇ i.e. the periods in which each compound is effective may overlap), although this is not essential.
- the microtubule stabilising agent and the sigma receptor ligand may be administered to the patient separately.
- Separate administration covers administering the microtubule stabilising agent and the sigma receptor ligand at substantially different points in time.
- separate administration may include administering a first composition, waiting for a period of time 'V, and then administering a second composition, ti may be in the range of 1 year to 6 months, 6 months to 1 month, 1 month to two weeks, two weeks to one week, one week to one day, 24 hours to 12 hours.
- i ⁇ may be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19 20, 21 , 22, 23 or 24 hours.
- t] is 0.5, 1 , 1.5, 2, 2.5 or 3 hours. In a more specific embodiment, t] is 1 hour. In a more specific embodiment, ti is 1 hour and the microtubule stabilising agent is given first followed by the sigma receptor ligand. Further compositions may additionally be administered as part of the separate administration, either at the same time as the first and second compositions, or at another time. If "n" further compositions are given, they may be each given at a periods of time "t n " after the second composition. Each t n independently has the same possible values as ti.
- the microtubule stabilising agent and the sigma receptor ligand may be given in any order.
- the microtubule stabilising agent may be given first followed by a sigma receptor ligand.
- the sigma receptor ligand may be given first, followed by the microtubule stabilising agent.
- the microtubule stabilising agent may be given once or twice daily for the first 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10 days of treatment. In any of the above embodiments, the microtubule stabilising agent may be given once daily for the first 1 , 2, 3, 4, or 5 days of treatment. In any of these embodiments, said agent may be a taxane and it is given for the first 5 days of treatment. In a more specific embodiment, said taxane is paclitaxel and it may be administered once daily for the first 5 days of treatment.
- the microtubule stabilising agent may be given in a metronomic regimen.
- a metronomic dosing regimen (also known as an anti-angiogenic dosing regimen) involves either continuous infusion or frequent administration without extended rest periods. This may be achieved by administering the drug as a continuous infusion at a low dose into the blood, or as a low dose bolus administered on a regular basis such as every day, every two days, every three days, every 4 days, every 5 days, every 6 days or every 7 days.
- the microtubule stabilising agent may be administered once every 1, 2, 3, 4, 5 or 6 days from the start of treatment, or, more specifically, once every 3 days from the start of treatment.
- paclitaxel may be given in a metronomic regimen. In such embodiments, paclitaxel may be administered once every 1, 2, 3, 4, 5 or 6 days or, more specifically, every 3 days from the start of treatment.
- sigma receptor ligands may be given once or twice daily as an oral tablet at a dose of up to about 800mg per tablet.
- said sigma receptor ligand is Rimcazole, as defined above.
- Rimcazole may be used or present in an amount between 0.1 mg and 500 mg per day.
- the microtubule stabilising agent may be administered on a three weekly cycle with a regimen of 2, 3, 4 or 6 cycles of three-weekly agent at a dose of between about 75mg/m 2 and about 225mg/m 2 , more specifically between about 100mg/m 2 and about 175mg/m 2 , more specifically about 75mg/m 2 , 100mg/m 2 , 135mg/m 2 , 175mg/m 2 or 225mg/m 2 .
- said agent is a taxane.
- said agent is paclitaxel, as defined above.
- microtubule stabilising agent and the sigma receptor ligand When the microtubule stabilising agent and the sigma receptor ligand are administered at the same time, they may be administered as a single pharmaceutical formulation or as two or more separate pharmaceutical formulations. When the microtubule stabilising agent and the sigma receptor ligand are not administered at the same time, they are administered as two or more separate pharmaceutical formulations.
- microtubule stabilising agent and the sigma receptor ligand are administered as separate pharmaceutical formulations, they may be administered by enteral or parenteral routes, including intravenous, intramuscular, subcutaneous, transdermal, airway (aerosol), oral, buccal, sublingual, intranasal, rectal, vaginal, and topical administration. In particular, they may be administered by intravenous, intramuscular, subcutaneous, oral, buccal, sublingual, rectal, vaginal, and/or topical means.
- microtubule stabilising agent and the sigma receptor ligand should be assessed for its biopharmaceutical properties, such as solubility and solution stability (across pH), permeability, etc., in order to select the most appropriate dosage form and route of administration for treatment of the proposed indication.
- each of the microtubule stabilising agent and the sigma receptor ligand may be administered as a formulation in association with one or more pharmaceutically acceptable excipients.
- excipient includes any ingredient other than the microtubule stabilising agent and the sigma receptor ligand which may impart either a functional (e.g drug release rate controlling) and/or a non-functional (e.g. processing aid or diluent) characteristic to the formulations.
- a functional e.g drug release rate controlling
- a non-functional e.g. processing aid or diluent
- the choice of excipient will to a large extent depend on factors such as the particular mode of administration, the effect of the excipient on solubility and stability, and the nature of the dosage form.
- Typical pharmaceutically acceptable excipients include:
- diluents e.g. lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine;
- lubricants e.g. silica, talcum, stearic acid, its magnesium or calcium salt and/or polyethyleneglycol;
- binders e.g. magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone
- disintegrants e.g. starches, agar, alginic acid or its sodium salt, or effervescent mixtures
- absorbants colorants, flavors and/or sweeteners.
- Each of the microtubule stabilising agent and/or the sigma receptor ligand may be administered orally.
- Oral administration may involve swallowing, so that the compound enters the gastrointestinal tract, and/or buccal, lingual, or sublingual administration by which the compound enters the blood stream directly from the mouth.
- Formulations suitable for oral administration include solid plugs, solid microparticulates, semi-solid and liquid (including multiple phases or dispersed systems) such as tablets; soft or hard capsules containing multi- or nano-particulates, liquids (e.g. aqueous solutions), emulsions or powders; lozenges (including liquid-filled); chews; gels; fast dispersing dosage forms; films; ovules; sprays; and buccal/mucoadhesive patches.
- solid plugs solid microparticulates, semi-solid and liquid (including multiple phases or dispersed systems) such as tablets; soft or hard capsules containing multi- or nano-particulates, liquids (e.g. aqueous solutions), emulsions or powders; lozenges (including liquid-filled); chews; gels; fast dispersing dosage forms; films; ovules; sprays; and buccal/mucoadhesive patches.
- Formulations suitable for oral administration may also be designed to deliver each of the microtubule stabilising agent and/or the sigma receptor ligand in an immediate release manner or in a rate-sustaining manner, wherein the release profile can be delayed, pulsed, controlled, sustained, or delayed and sustained or modified in such a manner which optimises the therapeutic efficacy of the said compounds.
- Means to deliver compounds in a rate-sustaining manner are known in the art and include slow release polymers that can be formulated with each of the microtubule stabilising agent and/or the sigma receptor ligand to control its release.
- rate-sustaining polymers include degradable and non-degradable polymers that can be used to release the said compounds by diffusion or a combination of diffusion and polymer erosion.
- rate-sustaining polymers include hydroxypropyl methylcellulose, hydroxypropyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, polyvinyl alcohol, polyvinyl pyrrolidone, xanthum gum, polymethacrylates, polyethylene oxide and polyethylene glycol.
- Liquid (including multiple phases and dispersed systems) formulations include emulsions, suspensions, solutions, syrups and elixirs. Such formulations may be presented as fillers in soft or hard capsules (made, for example, from gelatin or hydroxypropylmethylcellulose) and typically comprise a carrier, for example, water, ethanol, polyethylene glycol, propylene glycol, methylcellulose, or a suitable oil, and one or more emulsifying agents and/or suspending agents. Liquid formulations may also be prepared by the reconstitution of a solid, for example, from a sachet.
- microtubule stabilising agent and/or the sigma receptor ligand may also be used in fast-dissolving, fast-disintegrating dosage forms such as those described in Liang and Chen, Expert Opinion in Therapeutic Patents 2001 , 1 1(6): 981-986.
- microtubule stabilising agent and/or the sigma receptor ligand can be administered parenteral Iy.
- Each of the microtubule stabilising agent and/or the sigma receptor ligand may be administered directly into the blood stream, into subcutaneous tissue, into muscle, or into an internal organ.
- Suitable means for administration include intravenous, intraarterial, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular, intrasynovial and subcutaneous.
- Suitable devices for administration include needle (including microneedle) injectors, needle-free injectors and infusion techniques.
- Parenteral formulations are typically aqueous or oily solutions. Where the solution is aqueous, excipients such as sugars (including but restricted to glucose, mannitol, sorbitol, etc.) salts, carbohydrates and buffering agents (preferably to a pH of from 3 to 9), but, for some applications, they may be more suitably formulated as a sterile non-aqueous solution or as a dried form to be used in conjunction with a suitable vehicle such as sterile, pyrogen- free water (WFl).
- excipients such as sugars (including but restricted to glucose, mannitol, sorbitol, etc.) salts, carbohydrates and buffering agents (preferably to a pH of from 3 to 9), but, for some applications, they may be more suitably formulated as a sterile non-aqueous solution or as a dried form to be used in conjunction with a suitable vehicle such as sterile, pyrogen- free water (WFl).
- WFl sterile
- Parenteral formulations may include implants derived from degradable polymers such as polyesters (i.e. polylactic acid, polylactide, polylactide-co-glycolide, polycapro-lactone, polyhydroxybutyrate), polyorthoesters and polyanhydrides. These formulations may be administered via surgical incision into the subcutaneous tissue, muscular tissue or directly into specific organs.
- degradable polymers such as polyesters (i.e. polylactic acid, polylactide, polylactide-co-glycolide, polycapro-lactone, polyhydroxybutyrate), polyorthoesters and polyanhydrides.
- parenteral formulations under sterile conditions may readily be accomplished using standard pharmaceutical techniques well known to those skilled in the art.
- each of the microtubule stabilising agent and/or the sigma receptor ligand used in the preparation of parenteral solutions may be increased by the use of appropriate formulation techniques, such as the incorporation of co-solvents and/or solubility-enhancing agents such as surfactants, micelle structures and cyclodextrins.
- solubility-enhancing agents such as surfactants, micelle structures and cyclodextrins.
- each of the microtubule stabilising agent and/or the sigma receptor ligand can be administered intranasally or by inhalation, typically in the form of a dry powder (either alone, as a mixture, for example, in a dry blend with lactose, or as a mixed component particle, for example, mixed with phospholipids, such as phosphatidylcholine) from a dry powder inhaler, as an aerosol spray from a pressurised container, pump, spray, atomiser (preferably an atomiser using electrohydrodynamics to produce a fine mist), or nebuliser, with or without the use of a suitable propellant, such as 1 , 1 , 1 ,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoropropane, or as nasal drops.
- the powder may comprise a bioadhesive agent, for example, chitosan or cyclodextrin.
- the pressurised container, pump, spray, atomizer, or nebuliser contains a solution or suspension of the microtubule stabilising agent or the sigma receptor ligand comprising, for example, ethanol, aqueous ethanol, or a suitable alternative agent for dispersing, solubilising, or extending release of the active, a propellant(s) as solvent and an optional surfactant, such as sorbitan trioleate, oleic acid, or an oligolactic acid.
- a solution or suspension of the microtubule stabilising agent or the sigma receptor ligand comprising, for example, ethanol, aqueous ethanol, or a suitable alternative agent for dispersing, solubilising, or extending release of the active, a propellant(s) as solvent and an optional surfactant, such as sorbitan trioleate, oleic acid, or an oligolactic acid.
- the drug product Prior to use in a dry powder or suspension formulation, the drug product is micronised to a size suitable for delivery by inhalation (typically less than 5 microns). This may be achieved by any appropriate comminuting method, such as spiral jet milling, fluid bed jet milling, supercritical fluid processing to form nanoparticles, high pressure homogenisation, or spray drying.
- comminuting method such as spiral jet milling, fluid bed jet milling, supercritical fluid processing to form nanoparticles, high pressure homogenisation, or spray drying.
- Capsules made, for example, from gelatin or hydroxypropylmethylcellulose
- blisters and cartridges for use in an inhaler or insufflator may be formulated to contain a powder mix of the compound of the invention, a suitable powder base such as lactose or starch and a performance modifier such as 1 leucine, mannitol, or magnesium stearate.
- the lactose may be anhydrous or in the form of the monohydrate, preferably the latter.
- Other suitable excipients include dextran, glucose, maltose, sorbitol, xylitol, fructose, sucrose and trehalose.
- Formulations for inhaled/intranasal administration may be formulated to be immediate and/or modified release using, for example, PGLA.
- Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.
- transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the compound optionally with carriers, optionally a rate controlling barrier to deliver the compound of the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin.
- microtubule stabilising agent or the sigma receptor ligand may be administered alone or in combination with one or more other drugs (or as any combination thereof).
- the microtubule stabilising agent and the sigma receptor ligand are administered as a single pharmaceutical formulation.
- a single pharmaceutical formulation may be administered by enteral or parenteral routes, including intravenous, intramuscular, subcutaneous, transdermal, airway (aerosol), oral, buccal, sublingual, intranasal, rectal, vaginal, and topical administration.
- the single pharmaceutical agent may be formulated as an intravenous formulation, an intraperitoneal formulation or an oral formulation.
- Said single formulation may be an oral formulation.
- the microtubule stabilising agent and the sigma receptor ligand may be administered as a single formulation in association with one or more pharmaceutically acceptable excipients.
- excipient is as defined above in connection with the separate pharmaceutical formulations.
- a pharmaceutical preparation comprising a microtubule stabilising agent and a sigma receptor ligand may be administered orally.
- Oral administration may involve swallowing, so that the compound enters the gastrointestinal tract, and/or buccal, lingual, or sublingual administration by which the compound enters the blood stream directly from the mouth.
- Formulations suitable for oral administration include solid plugs, solid microparticulates, semi-solid and liquid (including multiple phases or dispersed systems) such as tablets; soft or hard capsules containing multi- or nano-particulates, liquids (e.g. aqueous solutions), emulsions or powders; lozenges (including liquid-filled); chews; gels; fast dispersing dosage forms; films; ovules; sprays; and buccal/mucoadhesive patches.
- solid plugs solid microparticulates, semi-solid and liquid (including multiple phases or dispersed systems) such as tablets; soft or hard capsules containing multi- or nano-particulates, liquids (e.g. aqueous solutions), emulsions or powders; lozenges (including liquid-filled); chews; gels; fast dispersing dosage forms; films; ovules; sprays; and buccal/mucoadhesive patches.
- Formulations suitable for oral administration may also be designed to deliver each of the microtubule stabilising agentand/or the sigma receptor ligand in an immediate release manner or in a rate-sustaining manner, wherein the release profile can be delayed, pulsed, controlled, sustained, or delayed and sustained or modified in such a manner which optimises the therapeutic efficacy of the said compounds.
- Means to deliver compounds in a rate-sustaining manner are known in the art and include slow release polymers that can be formulated with the microtubule stabilising agent and the sigma receptor ligand to control their release.
- rate-sustaining polymers include degradable and non-degradable polymers that can be used to release the said compounds by diffusion or a combination of diffusion and polymer erosion.
- rate-sustaining polymers include hydroxypropyl methylcellulose, hydroxypropyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, polyvinyl alcohol, polyvinyl pyrrolidone, xanthum gum, polymethacrylates, polyethylene oxide and polyethylene glycol.
- Liquid (including multiple phases and dispersed systems) formulations include emulsions, suspensions, solutions, syrups and elixirs. Such formulations may be presented as fillers in soft or hard capsules (made, for example, from gelatin or hydroxypropylmethylcellulose) and typically comprise a carrier, for example, water, ethanol, polyethylene glycol, propylene glycol, methylcellulose, or a suitable oil, and one or more emulsifying agents and/or suspending agents. Liquid formulations may also be prepared by the reconstitution of a solid, for example, from a sachet.
- microtubule stabilising agent and a sigma receptor ligand may also be used in fast-dissolving, fast-disintegrating dosage forms such as those described in Liang and Chen, Expert Opinion in Therapeutic Patents 2001, 1 1(6): 981-986.
- a pharmaceutical formulation comprising a microtubule stabilising agent and a sigma receptor ligand may be administered parenterally.
- the pharmaceutical formulation may be administered directly into the blood stream, into subcutaneous tissue, into muscle, or into an internal organ.
- Suitable means for administration include intravenous, intraarterial, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular, intrasynovial and subcutaneous.
- Suitable devices for administration include needle (including microneedle) injectors, needle-free injectors and infusion techniques.
- Parenteral formulations are typically aqueous or oily solutions. Where the solution is aqueous, excipients such as sugars (including but restricted to glucose, mannitol, sorbitol, etc.) salts, carbohydrates and buffering agents (preferably to a pH of from 3 to 9), but, for some applications, they may be more suitably formulated as a sterile non-aqueous solution or as a dried form to be used in conjunction with a suitable vehicle such as sterile, pyrogen- free water (WFI).
- excipients such as sugars (including but restricted to glucose, mannitol, sorbitol, etc.) salts, carbohydrates and buffering agents (preferably to a pH of from 3 to 9), but, for some applications, they may be more suitably formulated as a sterile non-aqueous solution or as a dried form to be used in conjunction with a suitable vehicle such as sterile, pyrogen- free water (WFI).
- WFI pyrogen- free water
- Parenteral formulations may include implants derived from degradable polymers such as polyesters (i.e. polylactic acid, polylactide, polylactide-co-glycolide, polycapro-lactone, polyhydroxybutyrate), polyorthoesters and polyanhydrides. These formulations may be administered via surgical incision into the subcutaneous tissue, muscular tissue or directly into specific organs.
- degradable polymers such as polyesters (i.e. polylactic acid, polylactide, polylactide-co-glycolide, polycapro-lactone, polyhydroxybutyrate), polyorthoesters and polyanhydrides.
- parenteral formulations under sterile conditions may readily be accomplished using standard pharmaceutical techniques well known to those skilled in the art.
- solubility of each of the microtubule stabilising agent and the sigma receptor ligand used in the preparation of parenteral solutions may be increased by the use of appropriate formulation techniques, such as the incorporation of co-solvents and/or solubility-enhancing agents such as surfactants, micelle structures and cyclodextrins.
- the combination of the microtubule stabilising agent and/or the sigma receptor ligand can be administered intranasally or by inhalation, typically in the form of a dry powder (either alone, as a mixture, for example, in a dry blend with lactose, or as a mixed component particle, for example, mixed with phospholipids, such as phosphatidylcholine) from a dry powder inhaler, as an aerosol spray from a pressurised container, pump, spray, atomiser (preferably an atomiser using electrohydrodynamics to produce a fine mist), or nebuliser, with or without the use of a suitable propellant, such as 1,1,1,2-tetrafluoroethane or 1 ,1,1,2,3,3,3-heptafluoropropane, or as nasal drops.
- the powder may comprise a bioadhesive agent, for example, chitosan or cyclodextrin.
- the pressurised container, pump, spray, atomizer, or nebuliser contains a solution or suspension of the microtubule stabilising agent and the sigma receptor ligand comprising, for example, ethanol, aqueous ethanol, or a suitable alternative agent for dispersing, solubilising, or extending release of the active, a propellant(s) as solvent and an optional surfactant, such as sorbitan trioleate, oleic acid, or an oligolactic acid.
- a solution or suspension of the microtubule stabilising agent and the sigma receptor ligand comprising, for example, ethanol, aqueous ethanol, or a suitable alternative agent for dispersing, solubilising, or extending release of the active, a propellant(s) as solvent and an optional surfactant, such as sorbitan trioleate, oleic acid, or an oligolactic acid.
- the drug product Prior to use in a dry powder or suspension formulation, the drug product is micronised to a size suitable for delivery by inhalation (typically less than 5 microns). This may be achieved by any appropriate comminuting method, such as spiral jet milling, fluid bed jet milling, supercritical fluid processing to form nanoparticles, high pressure homogenisation, or spray drying.
- comminuting method such as spiral jet milling, fluid bed jet milling, supercritical fluid processing to form nanoparticles, high pressure homogenisation, or spray drying.
- Capsules made, for example, from gelatin or hydroxypropylmethylcellulose
- blisters and cartridges for use in an inhaler or insufflator may be formulated to contain a powder mix of the compound of the invention, a suitable powder base such as lactose or starch and a performance modifier such as leucine, mannitol, or magnesium stearate.
- the lactose may be anhydrous or in the form of the monohydrate, preferably the latter.
- Other suitable excipients include dextran, glucose, maltose, sorbitol, xylitol, fructose, sucrose and trehalose.
- Formulations for inhaled/intranasal administration may be formulated to be immediate and/or modified release using, for example, PGLA.
- Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.
- transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the compound optionally with carriers, optionally a rate controlling barrier to deliver the compound of the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin.
- the present invention further provides a pharmaceutical composition comprising a combination of the invention and pharmaceutically acceptable excipients.
- the pharmaceutical composition comprising a combination of the invention is an anhydrous or lyophilised solid.
- the pharmaceutical composition comprising a combination of the invention is a solution, dispersion, emulsion, or suspension.
- said solvent can be any known pharmaceutically acceptable solvent, including water, ethanol and saline solution.
- the pharmaceutical composition is formulated into various dosage forms selected from a group comprising tablet, troches, lozenges, aqueous or oily suspensions, ointment, patch, gel, lotion, dentifrice, capsule, emulsion, creams, spray, drops, dispersible powders or granules, emulsion in hard or soft gel capsules, syrups and elixirs.
- dosage forms selected from a group comprising tablet, troches, lozenges, aqueous or oily suspensions, ointment, patch, gel, lotion, dentifrice, capsule, emulsion, creams, spray, drops, dispersible powders or granules, emulsion in hard or soft gel capsules, syrups and elixirs.
- the present invention further provides a kit comprising a microtubule stabilising agent selected from a taxane or a pharmaceutically acceptable derivative thereof, and a sigma receptor ligand.
- the kit may further comprise instructions for the separate, sequential and / or simultaneous administration of said agent and said ligand.
- the kit of the present invention may further comprise one or more devices for administering the combination therapy to a human patient such as one or more of (i) a sterile needle and syringe, (ii) a sterile container ⁇ e.g. a glass bottle, plastic bottle or plastic bag) and drip chamber, (iii) a sterile tube with a regulating clamp, and (iv) a catheter.
- compositions, kits and other compounds of the invention may be given by any of the routes discussed above.
- any of the combined medicaments of the invention may be given orally or intravenously.
- composition comprising X may consist exclusively of X or may include something additional e.g. X + Y.
- Figure 1 shows that Rimcazole and paclitaxel do not synergise to reduce MDA-MB-231 tumour cell viability in vitro;
- FIG. 2 shows that Rimcazole increases the percentage of cells in the Gl phase of cell cycle arrest
- Figure 3 shows that Rimcazole and paclitaxel in combination reduces the percentage of cells in G2/M and subGO arrest
- FIG. 4 shows that Rimcazole lacks single agent activity against large MDA-MB-231 tumours
- Figure 5 shows that paclitaxel administered according to a metronomic dosing schedule inhibits the growth of MDA-MB-231 xenograft tumours
- Figure 6 shows that paclitaxel inhibits the growth of MDA-MB-231 xenograft tumours when administered daily for 5 days;
- Figure 7 shows that Rimcazole and paclitaxel synergise to delay tumour growth when paclitaxel is administered according to a metronomic dosing schedule
- Figure 8 shows that a combination treatment with Rimcazole (22.5mg/kg/d) and paclitaxel (30mg/kg) synergises to delay tumour growth;
- Figure 9 shows that a combination treatment with Rimcazole (22.5mg/kg/d) and paclitaxel (15mg/kg) synergises to delay tumour growth;
- Figure 10 shows the effect of Rimcazole (22.5mg/kg/d) and paclitaxel (30mg/kg/days 1-5) on survival of xenografts-bearing mice.
- NCr nu/nu mice 7-8 week old female athymic mice (NCr nu/nu) were implanted subcutaneously on Day 0 with 30 to 60mg tumour fragments using a 12-gauge trocar needle. Animals were randomized into treatment groups on Day 13.
- mean estimated tumour mass for all groups at initiation of treatment was 281 mg (range of group means: 226-322mg) and paclitaxel was administered once daily for the first 5 days of treatment.
- mean estimated tumour mass for all groups at initiation of treatment was 206mg (range of group means: 195-226mg) and paclitaxel was administered once every three days from the start of treatment.
- Tumour burden (mg) (L x W2)/2, where L and W are the respective orthogonal tumour length and width measurements (mm).
- Tumour growth delay expressed as a T-C value, where T and C are the median times in days required for the treatment and control group tumours respectively to grow to 750mg.
- %T/C is defined as the median tumour mass of the Treated Group divided by the median tumour mass of the Control Group x 100. In this experiment, %T/C was evaluated when the median Control reached 2g.
- Tumour response a complete response (CR) is defined as a decrease in tumour mass to an undetectable size ( ⁇ 50mg), a partial response (PR) is defined as a > 50% decrease in tumour mass from that at first treatment.
- PRs are exclusive of CRs, as are Tumour-Free Survivors (TFS).
- TFS Tumour-Free Survivors
- Net Kill the change in tumour burden (logs) over the treatment period.
- the Net Kill value allows quantitative comparison of efficacy across multiple experimental protocols and across models by normalizing the efficacy data for treatment regimens of varied duration and differences in tumour growth rates between experiments or models. Positive values indicate that an actual reduction of tumour burden had occurred at the end of therapy relative to the pre-treatment burden. Negative values indicate the tumour grew (although possibly more slowly than the control tumours) during treatment. Thus, negative Net Kill values do not necessarily imply a complete lack of activity.
- Tumour-free survivors and tumour-bearing survivors whose tumours had not reached the Evaluation Size by the last day of the experiment were assigned a Time to Evaluation Size of > the last day of the experiment and were included in calculations of Tumour Growth Delay and Net Kill.
- the calculation of Net Kill by either method requires the establishment of the tumour doubling time (Td), which is the time in days for the tumour burden to double.
- Doubling time (Td) was estimated from the least squares best-fit straight line from a log-linear plot of tumour burden vs. time over the period of exponential growth ( ⁇ 200 to ⁇ 800mg range).
- Flow cytometric analysis was conducted on permeabilised MDA MB 231 cells that were then stained with the nucleic acid dye propidium iodide, following exposure to Rimcazole alone for 24 hours over a range of concentrations ( Figure 2) or paclitaxel alone at 30 ⁇ M and in combination with Rimcazole ( Figure 3).
- Rimcazole increased the percentage of cells in the Gl phase of the cell cycle ( Figure 2), indicating a partial Gl cell cycle arrest.
- XP/YR relates to X mg/kg/d of paclitaxel and Y mg/kg/d of Rimcazole.
- tumour growth delay Treatment resulted in a tumour growth delay of 8.8 days and an apparent net tumour cell kill value of -1.591ogs (Table 1). Treatment also resulted in a Day 21 T/C value of 20%, 20% partial regressions, 20% complete regressions, and 20% tumour-free survivors. These effects were greater than those seen with either treatment alone, which did not result in a greater number of tumour free survivors.
- the tumour growth delay was statistically significant compared to control and to paclitaxel alone.
- Figure 10 shows the effect of Rimcazole (22.5mg/kg/d) and paclitaxel (30mg/kg/days 1-5) on survival of xenografts-bearing mice. Combination treatment reduced tumour growth in the animals such that the time to reach the termination date was delayed.
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to novel combinations of a microtubule stabilising agent and a sigma receptor ligand for use in treating cancer.
Description
COMBINATION THERAPY COMPRISING A TAXANE AND A SIGMA RECEPTOR
LIGAND SAUCH AS RIMCAZOLE
TECHNICAL FIELD
The invention relates to compounds which, when used in combination, are surprisingly active against cancer. The invention also relates to methods of using these compounds, and compositions and kits that comprise these compounds.
BACKGROUND
Taxanes, a class of diterpenes originally derived from yew trees, are known to be effective in treating various cancers. They have been shown to promote the polymerisation of microtubules and thereby increase microtubule stability. The two taxanes currently licensed for use in humans are paclitaxel (Taxol™) and docetaxel (Taxotere™). Paclitaxel binds to GDP-tubulin and stops microtubule depolymerisation. This results in highly stabilised microtubules, thereby preventing normal cell function.
Paclitaxel is effective in the treatment of metastatic breast cancer (Dombernowsky et al., 1995 Seminars in Oncology 22(6): 13-17) and in a range of other solid tumours (Kaye 1995 Seminars in Oncology 22(2): 30-33). et al
Rimcazole is a sigma receptor ligand which has been shown to be effective in inhibiting the growth of tumours in preclinical tumour xenografts models (Spruce et al., 2004 Cancer Research 64: 4875-4886). Mechanistic studies (WO 00/00599) have shown that Rimcazole may synergise with agents such as colchicine, nocodazole, podophyllotoxin and vinblastine to depolymerise or destabilise microtubules.
The treatment of cancer using a taxane or a sigma receptor ligand (such as Rimcazole) has a number of problems. Administration of these agents has been associated with toxicity, leading to the use of sub-optimal doses and, in some cases, low efficacy. Furthermore, cancer therapy using these compounds in isolation can fail because cancers become resistant to the compound by mutation. In addition, further compounds are required in order to improve the selectivity of the treatment for different cancers, thereby allowing improved efficacy and/or reduced toxicity.
Accordingly, new treatments and regimens are required in order to overcome these problems and to improve the treatment of cancer. In particular, there is a need for improved treatments for cancer that have a reduced toxicity, improved efficacy and / or new anticancer selectivities.
SUMMARY OF INVENTION
The present inventors have surprisingly found that, when used in combination, a microtubule stabilising agent, such as a taxane, and a sigma receptor ligand, such as Rimcazole, are particularly effective in treating cancer, in particular breast cancer.
This is surprising because Rimcazole has been shown to be co-operative with microtubule destabilising agents in it's anti-tumour action (see WO 00/00599) whilst the taxanes are known stabilisers of microtubules. Given that Rimcazole is co-operative with microtubule destabilising agents, the skilled person would not have expected co-operation or synergy between Rimcazole and microtubule stabilising agents. Indeed, in vitro studies suggested that Rimcazole and paclitaxel have no co-operativity or synergy.
More specifically, in vitro experiments have showed that a combination of the present invention did not work together to improve tumour cell viability (see figure 1.) Indeed, in vitro studies suggested that Rimcazole and paclitaxel do not synergise to reduce MDA-MB- 231 tumour cell viability in vitro; that Rimcazole and paclitaxel in combination reduces the percentage of cells in G2/M and subGO arrest and that Rimcazole lacks single agent activity against large MDA-MB-231 tumours (see figures 1 - 4).
However, the inventors have surprisingly found that microtubule stabilising agents and sigma receptor ligands can be used in combination in treating cancer. Furthermore, the inventors have demonstrated that the efficacy of these compounds in combination is greater than their combined separate efficacies, i.e. the combination has an unexpected synergistic effect.
In this regard, the present invention provides a microtubule stabilising agent selected from: a taxane, or a pharmaceutically acceptable derivative thereof, and a sigma receptor ligand, for use in treating cancer, wherein said treatment involves administering said microtubule stabilising agent and said sigma receptor ligand separately, sequentially or simultaneously.
In a second aspect, the invention provides a microtubule stabilising agent selected from a taxane, or a pharmaceutically acceptable derivative thereof, for use in treating cancer in a patient, wherein the patient has been previously treated, or is currently being treated with, a sigma receptor ligand.
In a third aspect, the invention provides a microtubule stabilising agent selected from: a taxane, or a pharmaceutically acceptable derivative thereof, for use in a method of treating cancer in a patient, wherein the microtubule stabilising agent is prepared for simultaneous, separate or sequential administration with a sigma receptor ligand.
In a fourth aspect, the invention provides a sigma receptor ligand, for use in treating cancer in a patient, wherein the patient has been previously treated, or is currently being treated with a microtubule stabilising agent selected from: a taxane, or a pharmaceutically acceptable derivative thereof.
In a fifth aspect, the invention provides a sigma receptor ligand for use in treating cancer in a patient, wherein the sigma receptor ligand is prepared for simultaneous, separate or sequential administration with a microtubule stabilising agent selected from: a taxane, or a pharmaceutically acceptable derivative thereof.
In a sixth aspect, the invention provides the use of a microtubule stabilising agent selected from: a taxane, or a pharmaceutically acceptable derivative thereof, and a sigma receptor ligand, in a method of manufacturing a medicament for the treatment of cancer.
In a seventh aspect, the invention provides the use of a microtubule stabilising agent selected from: a taxane, or a pharmaceutically acceptable derivative thereof, in a method of manufacturing a medicament for the treatment of cancer, wherein said treatment comprises the administration of a sigma receptor ligand .
In an eighth aspect, the invention provides the use of a sigma receptor ligand in a method of manufacturing a medicament for the treatment of cancer, wherein said treatment comprises the administration of a microtubule stabilising agent selected from: a taxane, or a pharmaceutically acceptable derivative thereof.
In a ninth aspect, the invention provides the use of a microtubule stabilising agent selected from: a taxane, or a pharmaceutically acceptable derivative thereof, in a method of manufacturing a medicament for the treatment of a patient with cancer, wherein said patient has been previously treated, or is currently being treated with a sigma receptor ligand .
In a tenth aspect, the invention provides the use of a sigma receptor ligand in a method of manufacturing a medicament for the treatment of a patient with cancer, wherein said patient has been previously treated, or is currently being treated with a microtubule stabilising agent selected from: a taxane, or a pharmaceutically acceptable derivative thereof.
In an eleventh aspect, the invention provides a composition comprising a microtubule stabilising agent selected from: a taxane, or a pharmaceutically acceptable derivative thereof, and a sigma receptor ligand.
In a twelfth aspect, the invention provides a kit comprising a microtubule stabilising agent selected from: a taxane, or a pharmaceutically acceptable derivative thereof, and a sigma receptor ligand.
In a thirteenth aspect, the invention provides the use of any of the above compositions in therapy, wherein said therapy comprises the separate, sequential or simultaneous administration of a microtubule stabilising agent selected from: a taxane, or a pharmaceutically acceptable derivative thereof, and a sigma receptor ligand.
In a fourteenth aspect, the invention provides the use of any of the above compositions in a method of treating cancer, wherein said method comprises the separate, sequential or simultaneous administration of a microtubule stabilising agent selected from: a taxane, or a pharmaceutically acceptable derivative thereof, and a sigma receptor ligand.
In a fifteenth aspect, the invention provides a method of treatment of cancer in a patient in need thereof, wherein said method comprises administering to said patient a therapeutically effective amount of: a microtubule stabilising agent selected from: a taxane, or a pharmaceutically acceptable derivative thereof, and therapeutically effective amount of a sigma receptor ligand , wherein said a microtubule stabilising agent and said sigma receptor ligand are administered separately, sequentially or simultaneously.
In a sixteenth aspect, the invention provides a method of treatment of cancer in a patient in need thereof, wherein said method comprises administering to said patient a therapeutically effective amount of a microtubule stabilising agent selected from: a taxane, or a pharmaceutically acceptable derivative thereof, wherein a therapeutically effective amount of a sigma receptor ligand has been previously administered to said patient.
In a seventeenth aspect, the invention provides a method of treatment of cancer in a patient in need thereof, wherein said method comprises administering to said patient a therapeutically effective amount of a sigma receptor ligand , wherein a therapeutically effective amount of a microtubule stabilising agent selected from: a taxane, or a pharmaceutically acceptable derivative thereof has been previously administered to said patient.
In an eighteenth aspect, the invention provides a method of reducing the toxicity of a microtubule stabilising agent selected from: a taxane, or a pharmaceutically acceptable derivative thereof, by administering said microtubule stabilising agent in combination with a sigma receptor ligand.
In a nineteenth aspect, the invention provides a method of delaying the growth of a tumour by administering a microtubule stabilising agent selected from: a taxane, or a pharmaceutically acceptable derivative thereof in combination with a sigma receptor ligand.
In a twentieth aspect, the invention provides a method of prolonging the life span of a patient with cancer, by administrating a microtubule stabilising agent selected from: a
taxane, or a pharmaceutically acceptable derivative thereof in combination with a sigma receptor ligand.
In a twenty first aspect, the invention provides a method of treating breast cancer in a patient in need thereof, wherein said method comprises administering to said patient a therapeutically effective amount of paclitaxel, and a therapeutically effective amount of Rimcazole wherein said administration is separate, sequential or simultaneous.
In a twenty second aspect, the invention provides a method of treatment of cancer in a patient in need thereof, wherein said method comprises administering to said patient a therapeutically effective amount of A and a therapeutically effective amount of B, wherein A is a taxane, or a pharmaceutically acceptable derivative thereof, and B is a sigma receptor ligand , wherein A and B are administered separately, sequentially or simultaneously.
The microtubule stabilising agent
A microtubule stabilising agent is an agent that increases the stability of microtubules, an effect which can be observed in the microtubule stabilisation assays discussed in Shelanski et al. PNAS 70, 3, p765, 1973. Shelanski et al. describes how microtubule stabilisation may be measured by light scattering, preferably in combination with an electron microscope, and / or by using centrifugation.
The microtubule stabilising agent is a taxane or a pharmaceutically derivative thereof. Methods of synthesising microtubule stabilising agents are described in U.S. 4,924,011, U.S. 4,924,012 and U.S. 5,175,315.
The term "pharmaceutically acceptable derivative" includes pharmaceutically acceptable salts, solvates, hydrates, metabolites, prodrugs and isomers.
In any of the above aspects of the invention, the microtubule stabilising agent may be paclitaxel (taxol™), docetaxel (taxotere™), DHA-paclitaxel (taxoprexin™), polyglutimate- taxol (OPAXIO™), or a prodrug, pharmaceutically acceptable salt, solvate, hydrate, derivative, isomer or metabolite thereof. The microtubule stabilising agent is preferably paclitaxel (taxol™).
The microtubule stabilising agent can be formulated using any of the techniques known in the art. For example, it can be provided as a solid tablet, power, solution, dispersion, emulsion, or suspension. It can be formulated in liposomes, in polyethoxylated castor oil, in ethanol, bound to albumin and / or in tween 80™. In one embodiment, the agent is paclitaxel and it is formulated with polyethoxylated castor oil and / or ethanol. In another embodiment, the agent is docetaxel and it is formulated with albumin in saline solution.
Pharmaceutically acceptable salts of the taxane may include those of inorganic acids, for example, hydrohalic acids such as hydrochloric acid, hydrobromic acid or hydroiodic acid, nitric acid, sulfuric acid, phosphoric acid; and organic acids, for example aliphatic monocarboxylic acids such as formic acid, acetic acid, propionic acid and butyric acid, aliphatic hydroxy acids such as lactic acid, citric acid, tartaric acid or malic acid, dicarboxylic acids such as maleic acid or succinic acid, aromatic carboxylic acids such as benzoic acid, p-chlorobenzoic acid, diphenylacetic acid or triphenylacetic acid, aromatic hydroxy acids such as o-hydroxybenzoic acid, p-hydroxybenzoic acid, 1- hydroxynaphthalene-2-carboxylic acid or 3-hydroxynaphthalene-2-carboxylic acid, and sulfonic acids such as methanesulfonic acid or benzenesulfonic acid. These salts may be prepared by known salt-forming procedures.
If the microtubule stabilising agent contains acidic, e.g. carboxyl, groups, it may also be capable of forming salts with bases, in particular pharmaceutically acceptable bases such as those well known in the art; suitable such salts include metal salts, particularly alkali metal or alkaline earth metal salts such as sodium, potassium, magnesium or calcium salts, or salts with ammonia or pharmaceutically acceptable organic amines or heterocyclic bases such as ethanolamines, benzylamines or pyridine. These salts may be prepared by known salt- forming procedures.
The microtubule stabilising agent may be in the form of a prodrug. Said prodrug may be selected from the group consisting of esters, amides and hydrates.
The term pro-drug is also meant to include any covalently bonded carrier which releases the active compound of the invention in vivo when such prodrug is administered to a subject. Pro-drugs of a microtubule stabilising agent of the invention may be prepared by modifying functional groups present in the compound of the invention in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compound of the invention.
Where there is an asymmetric carbon atom the compounds exist in individual optically active isomeric forms or as mixtures thereof, e.g. as racemic or diastereomeric mixtures. The optically active compounds used in the invention embrace all individual optically active R and S isomers as well as mixtures, e.g. racemic or diastereomeric mixtures, thereof.
The present invention includes pharmaceutically acceptable isotopically-labeled versions of the microtubule stabilising agents mentioned herein. Said pharmaceutically acceptable isotopically-labeled versions of the compounds are compounds wherein one or more atoms from a compound mentioned herein are replaced by atoms having the same atomic number,
but an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
Examples of isotopes suitable for inclusion in the compounds of the invention comprises isotopes of hydrogen, such as 2H and 3H, carbon, such as 11C, 13C and 14C, chlorine, such as 36Cl, fluorine, such as 18F, iodine, such as 123I and 123I, nitrogen, such as 13N and 15N, oxygen, such as 15O, 17O and 18O, phosphorus, such as 32P, and sulphur, such as 33S.
Substitution with heavier isotopes such as deuterium, i.e. 2H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances.
Isotopically-labelled compounds mentioned herein can generally be prepared by the methods used in the art, for example, by modifying a known method for making a compound disclosed herein by using isotopically-labelled reagents.
The sigma receptor ligand
A sigma receptor ligand is a ligand that binds to the sigma receptor, an effect which can be observed in a sigma receptor binding assay (Vilner et al. Cancer Res 55(2):408-413, 1995 (see page 409, column 1, second paragraph). The binding of a putative sigma ligand to sites on sigma receptors, especially sigma 1 receptors can be measured by comparison to the prototypic sigma ligands such as (+)-pentazocine and 1 ,3-di-o-tolylguanidine (DTG). Radio- or chemically- labelled prototype sigma ligands are allowed to bind to sigma receptors in a cell preparation. The amount of labelled prototype sigma ligands displaced by the putative ligand is measured and used to calculate the affinity of the putative ligand for the sigma receptor.
If a putative sigma ligand has an affinity of less than lOμM, it is considered to be a sigma receptor ligand.
Examples of suitable sigma receptor ligands for use in the present invention include those listed in list 1 below:
List 1:
Rimcazole, Rimcazole dihydrochloride, Rimcazole hydrochloride, haloperidol, reduced haloperidol, IPAG (l -(4-iodophenyl)-3-(2-adamantyl)guanidine), BD- 1047 (N(-)[2-(3,4- dichlorophenyl)ethyl]-N-methyl-2-(dimethylamino)ethylamine), BD-1063 (l (-)[2-(3,4- dichlorophenyl)ethyl]-4-methylpiperazine), (+)-SKF- 10047 ((+)-N-allyl normetazocine), (+)-benzomorphans including (+)-petazocine and (+)-ethylketocyclazocine, (+)-morphinans including dextrallorphan, cis isomers of U50488 and analogues, arylcyclohexamines including PCP, N,N'-diryl-substituted guanidines including DTG (l ,3-di(2-tolyl)guanidine),
phenylpiperidines including (+)-3-PPP and OHBQs, steroids including progesterone and desoxycorticosterone, butryophenones, BD614,(+/-)-cis-N-methyl-N-[2-(3,4- dichlorophenyl)ethyl]-2-(l-pyrrolodinyl)cyclohexylamine, peφhenazine, fluphenazine, (-)- butaclamol, acetophenazine, trifluroperazine, molindone, pimozide, thioridazine, chlorpromazine, triflupromazine, BMY 14802, BMY 13980, remoxipride, tiospirone, cinpuperone WY47384, and antidepressants including amitriptyline and imipramine, and pharmaceutically acceptable derivatives thereof.
More specifically, suitable sigma receptor ligands for use in the present invention are selected from list 2 below.
List 2:
Rimcazole, haloperidol, reduced haloperidol, IPAG (l-(4-iodophenyl)-3-(2- adamantyl)guanidine), DTG (l ,3-di(2-tolyl)guanidine), cis isomers of U50488 and pharmaceutically acceptable derivatives thereof. In any one of the aspects of the invention, any one of the members of list 1 may be used, intended for use or formulated with paclitaxel.
In any one of the aspects of the invention, any one of the members of list 1 may be used, intended for use or formulated with docetaxel.
In any one of the aspects of the invention, any one of the members of list 1 may be used, intended for use or formulated with DHA-paclitaxel.
In any one of the aspects of the invention, any one of the members of list 1 may be used, intended for use or formulated with polyglutimate-taxol.
In any one of the aspects of the invention, any one of the members of list 2 may be used, intended for use or formulated with paclitaxel.
In any one of the aspects of the invention, any one of the members of list 2 may be used, intended for use or formulated with docetaxel.
In any one of the aspects of the invention, any one of the members of list 2 may be used, intended for use or formulated with DHA-paclitaxel.
In any one of the aspects of the invention, any one of the members of list 2 may be used, intended for use or formulated with polyglutimate-taxol.
In any of the above aspects of the invention, the sigma receptor ligand may be Rimcazole, or a pharmaceutically acceptable derivative thereof.
In any of the above aspects of the invention, the sigma receptor ligand may be specifically Rimcazole or a pharmaceutically acceptable salt thereof.
In any of the above aspects of the invention, the sigma receptor ligand may be Rimcazole.
The term "pharmaceutically acceptable derivative" includes pharmaceutically acceptable salts, solvates, hydrates, metabolites, prodrugs and isomers.
Rimcazole
9-[3-[3,5-dimethylpiperazin-l-yl]propyl]carbazole (BW 234U) is known as Rimcazole. Methods of synthesising Rimcazole are known in the art, e.g. as described in EP 0 012 208, US 5,955,459 and WO01/74359.
The term "pharmaceutically acceptable derivative" when applied to Rimcazole includes pharmaceutically acceptable salts, solvates, amides and prodrugs of Rimcazole.
Rimcazole has two stereogenic centres at the 3 and 5 positions of the piperazinyl ring and, as used herein, the term "Rimcazole" includes stereoisomers of Rimcazole. In one embodiment, the stereoisomer of Rimcazole is the (3S,5R) isomer, i.e. 9-[3-[(3S,5R)-3,5- dimethylpiperazin-l-yl]propyl]carbazole having the structural formula I:
Formula I
The term "pharmaceutically acceptable salt" of Rimcazole refers to non-toxic acidic/anionic salt forms.
Suitable pharmaceutically acceptable salts include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.
In one embodiment, the pharmaceutically acceptable salt is a hydrochloride salt of Rimcazole, typically the dihydrochloride salt (Rimcazole dihydrochloride). Preferably the salt is Rimcazole dihydrochloride, which is of structural formula II:
Formula II
The term "pharmaceutically acceptable solvate" includes hydrates or solvates formed with common organic solvents. In one embodiment, the hydrate is Rimcazole dihydrochloride monohydrate.
The Rimcazole or a pharmaceutically acceptable derivative thereof may have one or more polymorph or amorphous crystalline forms and are also included in the invention.
The term "pharmaceutically acceptable amide" includes compounds formed by the reaction of Rimcazole with a carboxylic acid, e.g. a Cl -6 carboxylic acid. The use of pharmaceutically acceptable amides as prodrugs is discussed, for example, in "The Theory and Practice of Industrial Pharmacy", 2nd Edition, Lachman, Lieberman & Kanig, 1976.
The term "prodrug" means a pharmaceutically acceptable form of a functional derivative of Rimcazole (or a salt thereof), wherein the prodrug may be: 1) a relatively active precursor which converts in vivo to an active prodrug component; 2) a relatively inactive precursor which converts in vivo to an active prodrug component; or 3) a relatively less active component of the compound that contributes to therapeutic biological activity after becoming available in vivo. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described in, for example, EP 0 012 208.
Treatment of diseases
As discussed above, the present invention is useful in the treatment cancer. In any of the above aspects of the present invention, the cancer may be cancer of the bladder, breast (female and / or male), kidney, lung, pancreas, prostate, skin, thyroid, liver, oesophagus, stomach, ovary, brain and/or central nervous system, uterus, bone and/or connective tissue and, in addition, the cancer may be leukaemia, melanoma, non-Hodgkin Lymphoma cervical, colorectal, myeloma, mesothelioma, oral, uterine, non-small cell lung carcinoma and Kaposi's sarcoma.
In any of the above embodiments of the invention, the cancer may be specifically any one of ovarian, breast, non-small cell lung carcinoma or Kaposi's sarcoma.
In any of the above embodiments of the invention, the cancer may be specifically breast cancer. In particular, the cancer may be hormone insensitive breast cancer. Hormone insensitive breast cancer may be more particularly defined as breast cancer which does not respond to hormone based breast cancer treatments.
The compounds of the present invention may be useful as both prophylactic and therapeutic treatments for cancer.
The term "wherein said patient has been previously treated with X" as used herein describes a distinct patient subgroup. In any of the above embodiments, this term defines a patient subgroup wherein said patients have been treated with X within the last 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19 20, 21, 22, 23 or 24 hours, 1 - ό days, 1 - 2 weeks, 1 — 5 month, 6 — 1 1 months and / or year.
The term "wherein said patient is currently being treated with X" as used herein describes a distinct patient subgroup. In any of the above embodiments, this term defines a patient subgroup wherein said patient is currently undergoing treatment with X, i.e. at that time X is being administered to the patient. In one embodiment, X may be being administered intravenously.
The amount of any compound or composition mentioned herein (or a pharmaceutically acceptable derivative thereof) administered as part of the invention should be a therapeutically effective amount where the any compound or composition mentioned herein is used for the treatment of a disease or condition, and a prophylactically effective amount where the compound or derivative is used for the prevention of a disease or condition.
As used herein, "treatment" includes prophylactic treatment. As used herein, a "patient" means an animal, e.g. a mammal, typically a human, in need of treatment.
The term "therapeutically effective amount" used herein refers to the amount of any compound or composition mentioned herein (or a pharmaceutically acceptable derivative thereof) needed to treat or ameliorate a targeted disease or condition. The term "prophylactically effective amount" used herein refers to the amount of compound needed to prevent a targeted disease or condition. The exact dosage will generally be dependent on the patient's status at the time of administration. Factors that may be taken into consideration when determining dosage include the severity of the disease state in the patient, the general health of the patient, the age, weight, gender, diet, time and frequency of administration, drug combinations, reaction sensitivities and the patient's tolerance or response to therapy.
The precise amount can be determined by routine experimentation, but may ultimately lie with the judgement of the clinician.
In one embodiment, the present invention relates to taxol and Rimcazole or a pharmaceutically acceptable derivative thereof for treating cancer, in particular breast cancer.
Administration & Formulation
In some embodiments, the microtubule stabilising agent and the sigma receptor ligand are administered to the patient at the same time. In these embodiments, the microtubule stabilising agent may be administered to the patient at exactly the same time as the sigma receptor ligand {i.e. the two compounds are administered simultaneously). Alternatively, the microtubule stabilising agent may be administered to the patient at approximately the same time as the sigma receptor ligand {i.e. the two therapies are not administered at precisely the same time ), e.g. during the same visit to a physician or healthcare professional.
In other embodiments, the microtubule stabilising agent and the sigma receptor ligand are not administered to the patient at the same time, but are administered sequentially (consecutively) in either order. In these embodiments, the methods of the present invention may comprise administering a microtubule stabilising agent to the patient before administering a sigma receptor ligand. Alternatively, the methods may comprise administering a microtubule stabilising agent to the patient after administering a sigma receptor ligand. In embodiments where the microtubule stabilising agent and the sigma receptor ligand are administered sequentially, the compounds may be administered in such a way that both compounds exert a therapeutic effect on the patient at the same time {i.e. the periods in which each compound is effective may overlap), although this is not essential.
In other embodiments, the microtubule stabilising agent and the sigma receptor ligand may be administered to the patient separately. Separate administration covers administering the microtubule stabilising agent and the sigma receptor ligand at substantially different points in time. For example, separate administration may include administering a first composition, waiting for a period of time 'V, and then administering a second composition, ti may be in the range of 1 year to 6 months, 6 months to 1 month, 1 month to two weeks, two weeks to one week, one week to one day, 24 hours to 12 hours. In particular, i\ may be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19 20, 21 , 22, 23 or 24 hours. In a more specific embodiment, t] is 0.5, 1 , 1.5, 2, 2.5 or 3 hours. In a more specific embodiment, t] is 1 hour. In a more specific embodiment, ti is 1 hour and the microtubule stabilising agent is given first followed by the sigma receptor ligand.
Further compositions may additionally be administered as part of the separate administration, either at the same time as the first and second compositions, or at another time. If "n" further compositions are given, they may be each given at a periods of time "tn" after the second composition. Each tn independently has the same possible values as ti.
In any of the above embodiments, the microtubule stabilising agent and the sigma receptor ligand may be given in any order. In a more specific embodiment, the microtubule stabilising agent may be given first followed by a sigma receptor ligand. In a different, more specific, embodiment, the sigma receptor ligand may be given first, followed by the microtubule stabilising agent.
In any of the above embodiments, the microtubule stabilising agent may be given once or twice daily for the first 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10 days of treatment. In any of the above embodiments, the microtubule stabilising agent may be given once daily for the first 1 , 2, 3, 4, or 5 days of treatment. In any of these embodiments, said agent may be a taxane and it is given for the first 5 days of treatment. In a more specific embodiment, said taxane is paclitaxel and it may be administered once daily for the first 5 days of treatment.
In any of the above embodiments, the microtubule stabilising agent may be given in a metronomic regimen. A metronomic dosing regimen (also known as an anti-angiogenic dosing regimen) involves either continuous infusion or frequent administration without extended rest periods. This may be achieved by administering the drug as a continuous infusion at a low dose into the blood, or as a low dose bolus administered on a regular basis such as every day, every two days, every three days, every 4 days, every 5 days, every 6 days or every 7 days. In such embodiments, the microtubule stabilising agent may be administered once every 1, 2, 3, 4, 5 or 6 days from the start of treatment, or, more specifically, once every 3 days from the start of treatment. In any of the disclosed embodiments, paclitaxel may be given in a metronomic regimen. In such embodiments, paclitaxel may be administered once every 1, 2, 3, 4, 5 or 6 days or, more specifically, every 3 days from the start of treatment.
In some embodiments, sigma receptor ligands may be given once or twice daily as an oral tablet at a dose of up to about 800mg per tablet. In one embodiment, said sigma receptor ligand is Rimcazole, as defined above. For example, in some embodiments Rimcazole may be used or present in an amount between 0.1 mg and 500 mg per day.
In some embodiments, the microtubule stabilising agent may be administered on a three weekly cycle with a regimen of 2, 3, 4 or 6 cycles of three-weekly agent at a dose of between about 75mg/m2 and about 225mg/m2, more specifically between about 100mg/m2 and about 175mg/m2, more specifically about 75mg/m2, 100mg/m2, 135mg/m2, 175mg/m2 or
225mg/m2. In one embodiment, said agent is a taxane. In one more specific embodiment, said agent is paclitaxel, as defined above.
When the microtubule stabilising agent and the sigma receptor ligand are administered at the same time, they may be administered as a single pharmaceutical formulation or as two or more separate pharmaceutical formulations. When the microtubule stabilising agent and the sigma receptor ligand are not administered at the same time, they are administered as two or more separate pharmaceutical formulations.
Administration as separate pharmaceutical formulations
Where the microtubule stabilising agent and the sigma receptor ligand are administered as separate pharmaceutical formulations, they may be administered by enteral or parenteral routes, including intravenous, intramuscular, subcutaneous, transdermal, airway (aerosol), oral, buccal, sublingual, intranasal, rectal, vaginal, and topical administration. In particular, they may be administered by intravenous, intramuscular, subcutaneous, oral, buccal, sublingual, rectal, vaginal, and/or topical means.
Each of the microtubule stabilising agent and the sigma receptor ligand should be assessed for its biopharmaceutical properties, such as solubility and solution stability (across pH), permeability, etc., in order to select the most appropriate dosage form and route of administration for treatment of the proposed indication.
In some embodiments, each of the microtubule stabilising agent and the sigma receptor ligand may be administered as a formulation in association with one or more pharmaceutically acceptable excipients. The term "excipient" includes any ingredient other than the microtubule stabilising agent and the sigma receptor ligand which may impart either a functional (e.g drug release rate controlling) and/or a non-functional (e.g. processing aid or diluent) characteristic to the formulations. The choice of excipient will to a large extent depend on factors such as the particular mode of administration, the effect of the excipient on solubility and stability, and the nature of the dosage form.
Typical pharmaceutically acceptable excipients include:
• diluents, e.g. lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine;
• lubricants, e.g. silica, talcum, stearic acid, its magnesium or calcium salt and/or polyethyleneglycol;
• binders, e.g. magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone;
• disintegrants, e.g. starches, agar, alginic acid or its sodium salt, or effervescent mixtures; and/or absorbants, colorants, flavors and/or sweeteners.
A thorough discussion of pharmaceutically acceptable excipients is available in Gennaro, Remington: The Science and Practice of Pharmacy 2000, 20th edition (ISBN: 0683306472).
Oral administration
Each of the microtubule stabilising agent and/or the sigma receptor ligand may be administered orally. Oral administration may involve swallowing, so that the compound enters the gastrointestinal tract, and/or buccal, lingual, or sublingual administration by which the compound enters the blood stream directly from the mouth.
Formulations suitable for oral administration include solid plugs, solid microparticulates, semi-solid and liquid (including multiple phases or dispersed systems) such as tablets; soft or hard capsules containing multi- or nano-particulates, liquids (e.g. aqueous solutions), emulsions or powders; lozenges (including liquid-filled); chews; gels; fast dispersing dosage forms; films; ovules; sprays; and buccal/mucoadhesive patches.
Formulations suitable for oral administration may also be designed to deliver each of the microtubule stabilising agent and/or the sigma receptor ligand in an immediate release manner or in a rate-sustaining manner, wherein the release profile can be delayed, pulsed, controlled, sustained, or delayed and sustained or modified in such a manner which optimises the therapeutic efficacy of the said compounds. Means to deliver compounds in a rate-sustaining manner are known in the art and include slow release polymers that can be formulated with each of the microtubule stabilising agent and/or the sigma receptor ligand to control its release.
Examples of rate-sustaining polymers include degradable and non-degradable polymers that can be used to release the said compounds by diffusion or a combination of diffusion and polymer erosion. Examples of rate-sustaining polymers include hydroxypropyl methylcellulose, hydroxypropyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, polyvinyl alcohol, polyvinyl pyrrolidone, xanthum gum, polymethacrylates, polyethylene oxide and polyethylene glycol.
Liquid (including multiple phases and dispersed systems) formulations include emulsions, suspensions, solutions, syrups and elixirs. Such formulations may be presented as fillers in soft or hard capsules (made, for example, from gelatin or hydroxypropylmethylcellulose) and typically comprise a carrier, for example, water, ethanol, polyethylene glycol, propylene glycol, methylcellulose, or a suitable oil, and one or more emulsifying agents and/or
suspending agents. Liquid formulations may also be prepared by the reconstitution of a solid, for example, from a sachet.
Each of the microtubule stabilising agent and/or the sigma receptor ligand may also be used in fast-dissolving, fast-disintegrating dosage forms such as those described in Liang and Chen, Expert Opinion in Therapeutic Patents 2001 , 1 1(6): 981-986.
The formulation of tablets is discussed in H. Lieberman and L. Lachman, Pharmaceutical Dosage Forms: Tablets 1980, vol. 1 (Marcel Dekker, New York).
Parenteral administration
Each of the microtubule stabilising agent and/or the sigma receptor ligand can be administered parenteral Iy.
Each of the microtubule stabilising agent and/or the sigma receptor ligand may be administered directly into the blood stream, into subcutaneous tissue, into muscle, or into an internal organ. Suitable means for administration include intravenous, intraarterial, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular, intrasynovial and subcutaneous. Suitable devices for administration include needle (including microneedle) injectors, needle-free injectors and infusion techniques.
Parenteral formulations are typically aqueous or oily solutions. Where the solution is aqueous, excipients such as sugars (including but restricted to glucose, mannitol, sorbitol, etc.) salts, carbohydrates and buffering agents (preferably to a pH of from 3 to 9), but, for some applications, they may be more suitably formulated as a sterile non-aqueous solution or as a dried form to be used in conjunction with a suitable vehicle such as sterile, pyrogen- free water (WFl).
Parenteral formulations may include implants derived from degradable polymers such as polyesters (i.e. polylactic acid, polylactide, polylactide-co-glycolide, polycapro-lactone, polyhydroxybutyrate), polyorthoesters and polyanhydrides. These formulations may be administered via surgical incision into the subcutaneous tissue, muscular tissue or directly into specific organs.
The preparation of parenteral formulations under sterile conditions, for example, by lyophilisation, may readily be accomplished using standard pharmaceutical techniques well known to those skilled in the art.
The solubility of each of the microtubule stabilising agent and/or the sigma receptor ligand used in the preparation of parenteral solutions may be increased by the use of appropriate formulation techniques, such as the incorporation of co-solvents and/or solubility-enhancing agents such as surfactants, micelle structures and cyclodextrins.
Inhalation & intranasal administration
Each of the microtubule stabilising agent and/or the sigma receptor ligand can be administered intranasally or by inhalation, typically in the form of a dry powder (either alone, as a mixture, for example, in a dry blend with lactose, or as a mixed component particle, for example, mixed with phospholipids, such as phosphatidylcholine) from a dry powder inhaler, as an aerosol spray from a pressurised container, pump, spray, atomiser (preferably an atomiser using electrohydrodynamics to produce a fine mist), or nebuliser, with or without the use of a suitable propellant, such as 1 , 1 , 1 ,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoropropane, or as nasal drops. For intranasal use, the powder may comprise a bioadhesive agent, for example, chitosan or cyclodextrin.
The pressurised container, pump, spray, atomizer, or nebuliser contains a solution or suspension of the microtubule stabilising agent or the sigma receptor ligand comprising, for example, ethanol, aqueous ethanol, or a suitable alternative agent for dispersing, solubilising, or extending release of the active, a propellant(s) as solvent and an optional surfactant, such as sorbitan trioleate, oleic acid, or an oligolactic acid.
Prior to use in a dry powder or suspension formulation, the drug product is micronised to a size suitable for delivery by inhalation (typically less than 5 microns). This may be achieved by any appropriate comminuting method, such as spiral jet milling, fluid bed jet milling, supercritical fluid processing to form nanoparticles, high pressure homogenisation, or spray drying.
Capsules (made, for example, from gelatin or hydroxypropylmethylcellulose), blisters and cartridges for use in an inhaler or insufflator may be formulated to contain a powder mix of the compound of the invention, a suitable powder base such as lactose or starch and a performance modifier such as 1 leucine, mannitol, or magnesium stearate. The lactose may be anhydrous or in the form of the monohydrate, preferably the latter. Other suitable excipients include dextran, glucose, maltose, sorbitol, xylitol, fructose, sucrose and trehalose.
Formulations for inhaled/intranasal administration may be formulated to be immediate and/or modified release using, for example, PGLA. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.
Transdermal administration
Suitable formμlations for transdermal application include a therapeutically effective amount of the microtubule stabilising agent or the sigma receptor ligand with carrier. Advantageous carriers include absorbable pharmacologically acceptable solvents to assist passage through
the skin of the host. Characteristically, transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the compound optionally with carriers, optionally a rate controlling barrier to deliver the compound of the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin.
The microtubule stabilising agent or the sigma receptor ligand may be administered alone or in combination with one or more other drugs (or as any combination thereof).
Administration as a single pharmaceutical formulation
In some embodiments of the present invention, the microtubule stabilising agent and the sigma receptor ligand are administered as a single pharmaceutical formulation. Such a single pharmaceutical formulation may be administered by enteral or parenteral routes, including intravenous, intramuscular, subcutaneous, transdermal, airway (aerosol), oral, buccal, sublingual, intranasal, rectal, vaginal, and topical administration. More specifically, the single pharmaceutical agent may be formulated as an intravenous formulation, an intraperitoneal formulation or an oral formulation. Said single formulation may be an oral formulation.
In some embodiments, the microtubule stabilising agent and the sigma receptor ligand may be administered as a single formulation in association with one or more pharmaceutically acceptable excipients. The term "excipient" is as defined above in connection with the separate pharmaceutical formulations.
Oral administration
A pharmaceutical preparation comprising a microtubule stabilising agent and a sigma receptor ligand may be administered orally. Oral administration may involve swallowing, so that the compound enters the gastrointestinal tract, and/or buccal, lingual, or sublingual administration by which the compound enters the blood stream directly from the mouth.
Formulations suitable for oral administration include solid plugs, solid microparticulates, semi-solid and liquid (including multiple phases or dispersed systems) such as tablets; soft or hard capsules containing multi- or nano-particulates, liquids (e.g. aqueous solutions), emulsions or powders; lozenges (including liquid-filled); chews; gels; fast dispersing dosage forms; films; ovules; sprays; and buccal/mucoadhesive patches.
Formulations suitable for oral administration may also be designed to deliver each of the microtubule stabilising agentand/or the sigma receptor ligand in an immediate release manner or in a rate-sustaining manner, wherein the release profile can be delayed, pulsed, controlled, sustained, or delayed and sustained or modified in such a manner which
optimises the therapeutic efficacy of the said compounds. Means to deliver compounds in a rate-sustaining manner are known in the art and include slow release polymers that can be formulated with the microtubule stabilising agent and the sigma receptor ligand to control their release.
Examples of rate-sustaining polymers include degradable and non-degradable polymers that can be used to release the said compounds by diffusion or a combination of diffusion and polymer erosion. Examples of rate-sustaining polymers include hydroxypropyl methylcellulose, hydroxypropyl cellulose, methyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, polyvinyl alcohol, polyvinyl pyrrolidone, xanthum gum, polymethacrylates, polyethylene oxide and polyethylene glycol.
Liquid (including multiple phases and dispersed systems) formulations include emulsions, suspensions, solutions, syrups and elixirs. Such formulations may be presented as fillers in soft or hard capsules (made, for example, from gelatin or hydroxypropylmethylcellulose) and typically comprise a carrier, for example, water, ethanol, polyethylene glycol, propylene glycol, methylcellulose, or a suitable oil, and one or more emulsifying agents and/or suspending agents. Liquid formulations may also be prepared by the reconstitution of a solid, for example, from a sachet.
The combination of a microtubule stabilising agent and a sigma receptor ligand may also be used in fast-dissolving, fast-disintegrating dosage forms such as those described in Liang and Chen, Expert Opinion in Therapeutic Patents 2001, 1 1(6): 981-986.
The formulation of tablets is discussed in H. Lieberman and L. Lachman, Pharmaceutical Dosage Forms: Tablets 1980, vol. 1 (Marcel Dekker, New York).
Parenteral administration
A pharmaceutical formulation comprising a microtubule stabilising agent and a sigma receptor ligand may be administered parenterally.
The pharmaceutical formulation may be administered directly into the blood stream, into subcutaneous tissue, into muscle, or into an internal organ. Suitable means for administration include intravenous, intraarterial, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular, intrasynovial and subcutaneous. Suitable devices for administration include needle (including microneedle) injectors, needle-free injectors and infusion techniques.
Parenteral formulations are typically aqueous or oily solutions. Where the solution is aqueous, excipients such as sugars (including but restricted to glucose, mannitol, sorbitol, etc.) salts, carbohydrates and buffering agents (preferably to a pH of from 3 to 9), but, for
some applications, they may be more suitably formulated as a sterile non-aqueous solution or as a dried form to be used in conjunction with a suitable vehicle such as sterile, pyrogen- free water (WFI).
Parenteral formulations may include implants derived from degradable polymers such as polyesters (i.e. polylactic acid, polylactide, polylactide-co-glycolide, polycapro-lactone, polyhydroxybutyrate), polyorthoesters and polyanhydrides. These formulations may be administered via surgical incision into the subcutaneous tissue, muscular tissue or directly into specific organs.
The preparation of parenteral formulations under sterile conditions, for example, by lyophilisation, may readily be accomplished using standard pharmaceutical techniques well known to those skilled in the art.
The solubility of each of the microtubule stabilising agent and the sigma receptor ligand used in the preparation of parenteral solutions may be increased by the use of appropriate formulation techniques, such as the incorporation of co-solvents and/or solubility-enhancing agents such as surfactants, micelle structures and cyclodextrins.
Inhalation & intranasal administration
The combination of the microtubule stabilising agent and/or the sigma receptor ligand can be administered intranasally or by inhalation, typically in the form of a dry powder (either alone, as a mixture, for example, in a dry blend with lactose, or as a mixed component particle, for example, mixed with phospholipids, such as phosphatidylcholine) from a dry powder inhaler, as an aerosol spray from a pressurised container, pump, spray, atomiser (preferably an atomiser using electrohydrodynamics to produce a fine mist), or nebuliser, with or without the use of a suitable propellant, such as 1,1,1,2-tetrafluoroethane or 1 ,1,1,2,3,3,3-heptafluoropropane, or as nasal drops. For intranasal use, the powder may comprise a bioadhesive agent, for example, chitosan or cyclodextrin.
The pressurised container, pump, spray, atomizer, or nebuliser contains a solution or suspension of the microtubule stabilising agent and the sigma receptor ligand comprising, for example, ethanol, aqueous ethanol, or a suitable alternative agent for dispersing, solubilising, or extending release of the active, a propellant(s) as solvent and an optional surfactant, such as sorbitan trioleate, oleic acid, or an oligolactic acid.
Prior to use in a dry powder or suspension formulation, the drug product is micronised to a size suitable for delivery by inhalation (typically less than 5 microns). This may be achieved by any appropriate comminuting method, such as spiral jet milling, fluid bed jet milling,
supercritical fluid processing to form nanoparticles, high pressure homogenisation, or spray drying.
Capsules (made, for example, from gelatin or hydroxypropylmethylcellulose), blisters and cartridges for use in an inhaler or insufflator may be formulated to contain a powder mix of the compound of the invention, a suitable powder base such as lactose or starch and a performance modifier such as leucine, mannitol, or magnesium stearate. The lactose may be anhydrous or in the form of the monohydrate, preferably the latter. Other suitable excipients include dextran, glucose, maltose, sorbitol, xylitol, fructose, sucrose and trehalose.
Formulations for inhaled/intranasal administration may be formulated to be immediate and/or modified release using, for example, PGLA. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.
Transdermal administration
Suitable formulations for transdermal application include a therapeutically effective amount of the microtubule stabilising agent and the sigma receptor ligand with carrier. Advantageous carriers include absorbable pharmacologically acceptable solvents to assist passage through the skin of the host. Characteristically, transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the compound optionally with carriers, optionally a rate controlling barrier to deliver the compound of the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin.
The present invention further provides a pharmaceutical composition comprising a combination of the invention and pharmaceutically acceptable excipients.
In one embodiment, the pharmaceutical composition comprising a combination of the invention is an anhydrous or lyophilised solid.
In a further embodiment, the pharmaceutical composition comprising a combination of the invention is a solution, dispersion, emulsion, or suspension. Where such compositions require a solvent, said solvent can be any known pharmaceutically acceptable solvent, including water, ethanol and saline solution.
In still another embodiment of the present invention, the pharmaceutical composition is formulated into various dosage forms selected from a group comprising tablet, troches, lozenges, aqueous or oily suspensions, ointment, patch, gel, lotion, dentifrice, capsule, emulsion, creams, spray, drops, dispersible powders or granules, emulsion in hard or soft gel capsules, syrups and elixirs.
Dosages for the methods, uses and composition of the invention will of course vary depending, for example, on the particular condition to be treated, the effect desired and the mode of administration. In general, suitable daily dosages for oral administration are of the order of 0.1 to 10 mg/kg.
The present invention further provides a kit comprising a microtubule stabilising agent selected from a taxane or a pharmaceutically acceptable derivative thereof, and a sigma receptor ligand. The kit may further comprise instructions for the separate, sequential and / or simultaneous administration of said agent and said ligand. Alternatively or in addition, the kit of the present invention may further comprise one or more devices for administering the combination therapy to a human patient such as one or more of (i) a sterile needle and syringe, (ii) a sterile container {e.g. a glass bottle, plastic bottle or plastic bag) and drip chamber, (iii) a sterile tube with a regulating clamp, and (iv) a catheter.
The combinations, compositions, kits and other compounds of the invention may be given by any of the routes discussed above.
In particular embodiments, any of the combined medicaments of the invention may be given orally or intravenously.
General
The term "comprising" encompasses "including" as well as "consisting" e.g. a composition "comprising" X may consist exclusively of X or may include something additional e.g. X + Y.
The word "substantially" does not exclude "completely" e.g. a composition which is "substantially free" from Y may be completely free from Y. Where necessary, the word "substantially" may be omitted from the definition of the invention.
The term "about" in relation to a numerical value x means, for example, x+10%.
The invention is further illustrated by reference to the following figures and non-limiting examples.
Description of the figures:
Figure 1 shows that Rimcazole and paclitaxel do not synergise to reduce MDA-MB-231 tumour cell viability in vitro;
Figure 2 shows that Rimcazole increases the percentage of cells in the Gl phase of cell cycle arrest;
Figure 3 shows that Rimcazole and paclitaxel in combination reduces the percentage of cells in G2/M and subGO arrest;
Figure 4 shows that Rimcazole lacks single agent activity against large MDA-MB-231 tumours;
Figure 5 shows that paclitaxel administered according to a metronomic dosing schedule inhibits the growth of MDA-MB-231 xenograft tumours;
Figure 6 shows that paclitaxel inhibits the growth of MDA-MB-231 xenograft tumours when administered daily for 5 days;
Figure 7 shows that Rimcazole and paclitaxel synergise to delay tumour growth when paclitaxel is administered according to a metronomic dosing schedule;
Figure 8 shows that a combination treatment with Rimcazole (22.5mg/kg/d) and paclitaxel (30mg/kg) synergises to delay tumour growth;
Figure 9 shows that a combination treatment with Rimcazole (22.5mg/kg/d) and paclitaxel (15mg/kg) synergises to delay tumour growth; and
Figure 10 shows the effect of Rimcazole (22.5mg/kg/d) and paclitaxel (30mg/kg/days 1-5) on survival of xenografts-bearing mice.
Examples
In vitro studies
In vitro assessment of cell viability was carried out using the MTS viability assay as previously described (Malich G et al, Toxicology, 124(3), pp. 179-192, 1997). Assessment of cell cycle was conducted using flow cytometric analysis (FACS). This method is well known in the art and measures the percentage of cells in different phases of the cell division cycle according to DNA content, in addition to cells with subnormal DNA content (sub GO) that represent late stage apoptotic cells. For in vitro studies paclitaxel was used with an ethanol vehicle.
Xenografts
7-8 week old female athymic mice (NCr nu/nu) were implanted subcutaneously on Day 0 with 30 to 60mg tumour fragments using a 12-gauge trocar needle. Animals were randomized into treatment groups on Day 13. For standard paclitaxel administration studies, mean estimated tumour mass for all groups at initiation of treatment was 281 mg (range of group means: 226-322mg) and paclitaxel was administered once daily for the first 5 days of treatment. For metronomic paclitaxel administration studies, mean estimated tumour mass
for all groups at initiation of treatment was 206mg (range of group means: 195-226mg) and paclitaxel was administered once every three days from the start of treatment. On days when combination treatment occurred, the animals were treated with paclitaxel first followed by treatment with Rimcazole within one hour. All animals were dosed according to individual body weight on the day of treatment (30mg/kg/d for Rimcazole and 30mg/kg every 3 days for paclitaxel). Paclitaxel metronomic administration was achieved by administering the drug once every three days. Paclitaxel was administered in cremaphor. (10%Ethanol/10%cremophor/80%water). Rimcazole was administered once daily by oral gavage as a solution in water.
Body weights and tumour measurements were recorded three times weekly. Tumour burden (mg) was estimated from calliper measurements by the formula for the volume of a prolate ellipsoid assuming unit density as: Tumour burden (mg) = (L x W2)/2, where L and W are the respective orthogonal tumour length and width measurements (mm).
Evaluation of efficacy
The following endpoints were used to evaluate the efficacy of Rimcazole and paclitaxel:
Tumour growth delay expressed as a T-C value, where T and C are the median times in days required for the treatment and control group tumours respectively to grow to 750mg. %T/C is defined as the median tumour mass of the Treated Group divided by the median tumour mass of the Control Group x 100. In this experiment, %T/C was evaluated when the median Control reached 2g.
Tumour response a complete response (CR) is defined as a decrease in tumour mass to an undetectable size (<50mg), a partial response (PR) is defined as a > 50% decrease in tumour mass from that at first treatment.
PRs are exclusive of CRs, as are Tumour-Free Survivors (TFS). Net LoglO Tumour Cell Kill (Net Kill) the change in tumour burden (logs) over the treatment period. The Net Kill value allows quantitative comparison of efficacy across multiple experimental protocols and across models by normalizing the efficacy data for treatment regimens of varied duration and differences in tumour growth rates between experiments or models. Positive values indicate
that an actual reduction of tumour burden had occurred at the end of therapy relative to the pre-treatment burden. Negative values indicate the tumour grew (although possibly more slowly than the control tumours) during treatment. Thus, negative Net Kill values do not necessarily imply a complete lack of activity. Tumour-free survivors and tumour-bearing survivors whose tumours had not reached the Evaluation Size by the last day of the experiment were assigned a Time to Evaluation Size of > the last day of the experiment and were included in calculations of Tumour Growth Delay and Net Kill. The calculation of Net Kill by either method requires the establishment of the tumour doubling time (Td), which is the time in days for the tumour burden to double. Doubling time (Td) was estimated from the least squares best-fit straight line from a log-linear plot of tumour burden vs. time over the period of exponential growth (~200 to ~800mg range).
Statistics
Graphical data were analysed using a standard students t-test. Results are shown in comparison to control.
Results
In vitro studies show a lack of co-operativity or synergy between Rimcazole and paclitaxel in either incuding cell death (figure 1) or in changing the cell cycle stage of the cells (figure 2) as assessed by FACS analysis. Assessment of viable cell number in cultured ER negative mammary carcinoma (MDA MB 231) cells using the MTS viabilioty assay which measures the metabolic activity of cells, exposed to Rimcazole or paclitaxel alone and in combination for a period of 24 hours revealed either no added benefit or modest antagonism between the two agents (Figure 1). Values are expressed as mean percentage viability ± SEM compared to the vehicle control. When paclitaxel 30μM and Rimcazole lOuM were combined, there was a slight increase in viable cell number compared to the value for paclitaxel alone, indicating antagonism between the two agents. When paclitaxel lOμM and Rimcazole lOμM were combined, there was a less than additive effect, again suggesting antagonism between the two.
Further evidence for antagonism between paclitaxel and Rimcazole was also revealed in an analysis of cell cycle profile. Flow cytometric analysis (FACS) was conducted on permeabilised MDA MB 231 cells that were then stained with the nucleic acid dye propidium iodide, following exposure to Rimcazole alone for 24 hours over a range of concentrations (Figure 2) or paclitaxel alone at 30μM and in combination with Rimcazole (Figure 3). Rimcazole increased the percentage of cells in the Gl phase of the cell cycle (Figure 2), indicating a partial Gl cell cycle arrest. In contrast, cells exposed to paclitaxel alone (Figure 3, left hand group of bars) displayed an increase in the percentage of cells in a
G2/M phase, indicating a G2/M cell cycle arrest compared to cells treated with no drugs (Figure 2, left hand bars). When cells were exposed to Rimcazole and paclitaxel in combination, there was a reduction in the percentage of cells in G2/M and subGO (Figure 3), indicating antagonism of both the G2/M cell cycle arrest, as well as apoptosis induction. Together, these data teach against the combination of Rimcazole with paclitaxel.
In vivo studies with Rimcazole and paclitaxel showed surprising data, given their lack of synergy in these in vitro studies.
Treatment with Rimcazole, as a single agent failed to produce anti-cancer activity against MDA-MB-231 xenografts at any dosage level (30, 22.5, 10, and 3mg/kg, see figure 4). In contrast, paclitaxel administered according to a metronomic schedule whereby administration was once every three days and therefore lacking the long rest period that is characteristic of more standard paclitaxel dosing regimens resulted in a delay in tumour growth (Figure 5)
This effect was increased by administration of paclitaxel on a repeat basis for the first 5 days of the study (Figure 6). Using this administration schedule, paclitaxel produced 20% complete regressions. The animals experiencing regression remained tumour-free at termination of the experiment. Standard paclitaxel treatment resulted in tumour growth delays of <2.4 days, associated apparent net tumour cell kill values of <-0.721ogs, and Day 21 T/C values of >46%. However, neither the time to evaluation size nor the Day 21 %T/C values were statistically significant. (Table 1)
Table 1. Measured tumour parameters for Rimcazole and standard paclitaxel treatment of MDA-MB-231 xenografts
Wherein XP/YR relates to X mg/kg/d of paclitaxel and Y mg/kg/d of Rimcazole.
When Rimcazole was combined with paclitaxel on a metronomic dosing schedule tumour growth was delayed by a greater margin that that seen for Rimcazole alone, which had no effect on tumour growth, and for paclitaxel alone (Figure 7).
This synergistic effect was further enhanced when paclitaxel was administered as a daily treatment for the first 5 days of the study (figures 8 and 9). Combination treatment with Rimcazole (22.5mg/kg), in combination with paclitaxel (30mg/kg), produced striking and statistically significant anti-cancer activity against MDA-MB-231 xenografts (Figure 8). The data showed that the combination of Rimcazole and paclitaxel together was able to regress tumour size back to the size of the originally implanted tumours, whilst neither Rimcazole nor paclitaxel alone were able to cause any shrinkage of tumours, or a growth delay of such magnitude. Treatment resulted in a tumour growth delay of 8.8 days and an apparent net tumour cell kill value of -1.591ogs (Table 1). Treatment also resulted in a Day 21 T/C value of 20%, 20% partial regressions, 20% complete regressions, and 20% tumour-free survivors. These effects were greater than those seen with either treatment alone, which did not result in a greater number of tumour free survivors. The tumour growth delay was statistically significant compared to control and to paclitaxel alone.
A similar effect was seen when Rimcazole (22.5mg/kg/d) was administered in combination with paclitaxel at 15mg/kg (Figure 9). This treatment resulted in a tumour growth delay of 3.0 days, an associated apparent net tumour cell kill value of -1.751ogs, and Day 21 T/C value of 34%. Treatment also resulted in 10% complete regressions, 10% partial regressions, and 10% tumour-free survivors. The tumour growth delay produced by treatment was statistically significant compared to the Control Group (Table 1). Neither agent alone caused an increase in tumour-free survivors. As such the action of the agents in combination was particularly surprising.
Figure 10 shows the effect of Rimcazole (22.5mg/kg/d) and paclitaxel (30mg/kg/days 1-5) on survival of xenografts-bearing mice. Combination treatment reduced tumour growth in the animals such that the time to reach the termination date was delayed.
Claims
1. A microtubule stabilising agent selected from a taxane, or a pharmaceutically acceptable derivative thereof, and a sigma receptor ligand, for use in treating cancer, wherein said treatment involves administering said microtubule stabilising agent and said sigma receptor ligand separately, sequentially or simultaneously.
2. A microtubule stabilising agent selected from a taxane or a pharmaceutically acceptable derivative thereof, for use in treating cancer in a patient, wherein the patient has been previously treated, or is currently being treated with, a sigma receptor ligand.
3. A microtubule stabilising agent selected from a taxane or a pharmaceutically acceptable derivative thereof, for use in a method of treating cancer in a patient, wherein the microtubule stabilising agent is prepared for simultaneous, separate or sequential administration with a sigma receptor ligand.
4. A microtubule stabilising agent according to any one of claims 1 to 3, wherein said agent is paclitaxel (taxol™), docetaxel (taxotere™), DHA-paclitaxel (taxoprexin™), polyglutimate-taxol (OPAXIO™), or a pharmaceutically acceptable derivative thereof.
5. A microtubule stabilising agent according to any one of claims 1 to 4, wherein said agent is paclitaxel (taxol™).
6. A microtubule stabilising agent according to any one of claims 1 to 5, wherein said sigma receptor ligand is Rimcazole, haloperidol, reduced haloperidol, IPAG (l-(4- iodophenyl)-3-(2-adamantyl)guanidine), DTG (l,3-di(2-tolyl)guanidine), cis isomers of U50488, or a pharmaceutically acceptable derivative thereof.
7. A microtubule stabilising agent according to any one of claims 1 to 6, wherein said sigma receptor ligand is Rimcazole or a pharmaceutically acceptable derivative thereof.
8. A microtubule stabilising agent according to any one of claims 1 to 7, wherein said sigma receptor ligand is Rimcazole or a pharmaceutically acceptable salt thereof.
9. A microtubule stabilising agent according to any one of claims 1 to 8, wherein said cancer is ovarian, breast, non-small cell lung carcinoma or Kaposi's sarcoma.
10. A microtubule stabilising agent according to claim 9, wherein said cancer is breast cancer.
1 1. A sigma receptor ligand, for use in treating cancer in a patient, wherein the patient has been previously treated, or is currently being treated with a microtubule stabilising agent selected from a taxane or a pharmaceutically acceptable derivative thereof.
12. A sigma receptor ligand for use in treating cancer in a patient, wherein the sigma receptor ligand is prepared for simultaneous, separate or sequential administration with a microtubule stabilising agent selected from a taxane, or pharmaceutically acceptable derivative thereof.
13. A sigma receptor ligand according to any one of claims 11 or 12, wherein said ligand is Rimcazole, haloperidol, reduced haloperidol, IPAG (l-(4-iodophenyl)-3-(2- adamantyl)guanidine), DTG (l,3-di(2-tolyl)guanidine), cis isomers of U50488, or a pharmaceutically acceptable derivative thereof.
14. A sigma receptor ligand according to any one of claims 1 1 to 13, wherein said ligand is Rimcazole or a pharmaceutically acceptable derivative thereof.
15. A sigma receptor ligand according to any one of claims 11 to 14, wherein said microtubule stabilising agent is paclitaxel (taxol™), docetaxel (taxotere™), DHA- paclitaxel (taxoprexin™), polyglutimate-taxol (OPAXIO™), or a pharmaceutically acceptable derivative thereof.
16. A sigma receptor ligand according to any one of claims 11 to 15, wherein said microtubule stabilising agent is paclitaxel (taxol™).
17. A sigma receptor ligand according to any one of claims 11 to 16, wherein said ligand is Rimcazole or a pharmaceutically acceptable salt thereof.
18. A sigma receptor ligand according to any one of claims 1 1 to 17, wherein said cancer is ovarian, breast, non-small cell lung carcinoma or Kaposi's sarcoma.
19. A sigma receptor ligand according to claim 18, wherein said cancer is breast cancer.
20. The use of a microtubule stabilising agent selected from a taxane or a pharmaceutically acceptable derivative thereof and a sigma receptor ligand, in a method of manufacturing a medicament for the treatment of cancer.
21. The use of a microtubule stabilising agent selected from a taxane or a pharmaceutically acceptable derivative thereof, in a method of manufacturing a medicament for the treatment of cancer, wherein said treatment comprises the administration of a sigma receptor ligand.
22. The use of a sigma receptor ligand in a method of manufacturing a medicament for the treatment of cancer, wherein said treatment comprises the administration of a microtubule stabilising agent selected from a taxane or a pharmaceutically acceptable derivative thereof.
23. The use of a microtubule stabilising agent selected from a taxane or a pharmaceutically acceptable derivative thereof, in a method of manufacturing a medicament for the treatment of a patient with cancer, wherein said patient has been previously treated, or is currently being treated with a sigma receptor ligand.
24. The use of a sigma receptor ligand in a method of manufacturing a medicament for the treatment of a patient with cancer, wherein said patient has been previously treated, or is currently being treated with a microtubule stabilising agent selected from a taxane or a pharmaceutically acceptable derivative thereof.
25.A use according to any one of claims 20 to 24, wherein said microtubule stabilising agent is paclitaxel (taxol™), docetaxel (taxotere™), DHA-paclitaxel (taxoprexin™), polyglutimate-taxol (OPAXIO™), or a pharmaceutically acceptable derivative thereof.
26. A use according to any one of claims 20 to 25, wherein said microtubule stabilising agent is paclitaxel (taxol™).
27. A use according to any one of claims 20 to 26, wherein said sigma receptor ligand is
Rimcazole, haloperidol, reduced haloperidol, IPAG (l-(4-iodophenyl)-3-(2- adamantyl)guanidine), DTG (l,3-di(2-tolyl)guanidine), cis isomers of U50488, or a pharmaceutically acceptable derivative thereof.
28. A use according to any one of claims 20 to 27, wherein said sigma receptor ligand is Rimcazole or a pharmaceutically acceptable derivative thereof.
29. A use according to any one of claims 20 to 28, wherein said sigma receptor ligand is Rimcazole or a pharmaceutically acceptable salt thereof.
30. A use according to any one of claims 20 to 29, wherein said cancer is ovarian, breast, non-small cell lung carcinoma or Kaposi's sarcoma.
31. A use according to claim 30, wherein said cancer is breast cancer.
32. A composition comprising a microtubule stabilising agent selected from a taxane or a pharmaceutically acceptable derivative thereof and a sigma receptor ligand.
33. A composition according to claim 32, wherein said composition also comprises at least one pharmaceutically acceptable excipient.
34. A composition according to claim 32 or claim 33, wherein said microtubule stabilising agent is paclitaxel (taxol™), docetaxel (taxotere™), DHA-paclitaxel (taxoprexin™), polyglutimate-taxol (OPAX1O™), or a pharmaceutically acceptable derivative thereof.
35. A composition according to any one of claims 32 to 34, wherein said microtubule stabilising agent is paclitaxel (taxol™).
36. A composition according to any one of claims 32 to 35, wherein said sigma receptor ligand is Rimcazole, haloperidol, reduced haloperidol, IPAG (l-(4-iodophenyl)-3-(2- adamantyl)guanidine), DTG (l,3-di(2-tolyl)guanidine), cis isomers of U50488, or a pharmaceutically acceptable derivative thereof.
37. A composition according to any one of claims 32 to 36, wherein said sigma receptor ligand is Rimcazole or a pharmaceutically acceptable salt thereof.
38. A kit comprising a microtubule stabilising agent selected from a taxane or a pharmaceutically acceptable derivative thereof and a sigma receptor ligand.
39. A kit according to claim 38, wherein said microtubule stabilising agent is paclitaxel (taxol™), docetaxel (taxotere™), DHA-paclitaxel (taxoprexin™), polyglutimate-taxol (OPAXIO™), or a pharmaceutically acceptable derivative thereof.
40. A kit according to any one of claims 38 and 39, wherein said microtubule stabilising agent is paclitaxel (taxol™).
41. A kit according to any one of claims 38 to 40, wherein said sigma receptor ligand is Rimcazole, haloperidol, reduced haloperidol, IPAG (l-(4-iodophenyl)-3-(2- adamantyl)guanidine), DTG (l ,3-di(2-tolyl)guanidine), cis isomers of U50488, or a pharmaceutically acceptable derivative thereof.
42. A kit according to any one of claims 38 to 41, wherein said sigma receptor ligand is Rimcazole or a pharmaceutically acceptable salt thereof.
43. The use of a composition of any of claims 32 to 37 in therapy, wherein said therapy comprises the separate, sequential or simultaneous administration of a microtubule stabilising agent selected from a taxane or a pharmaceutically acceptable derivative thereof and a sigma receptor ligand.
44. The use of a composition of any of claims 32 to 37 in a method of treating cancer, wherein said method comprises the separate, sequential or simultaneous administration of a microtubule stabilising agent selected from a taxane or a pharmaceutically acceptable derivative thereof and a sigma receptor ligand.
45. A method of treatment of cancer in a patient in need thereof, wherein said method comprises administering to said patient a therapeutically effective amount of: a microtubule stabilising agent selected from a taxane or a pharmaceutically acceptable derivative thereof and a therapeutically effective amount of a sigma receptor ligand, wherein said microtubule stabilising agent and said sigma receptor ligand are administered separately, sequentially or simultaneously.
46. A method of treatment of cancer in a patient in need thereof, wherein said method comprises administering to said patient a therapeutically effective amount of a microtubule stabilising agent selected from a taxane or a pharmaceutically acceptable derivative thereof, wherein a therapeutically effective amount of a sigma receptor ligand has been previously administered to said patient.
47. A method of treatment of cancer in a patient in need thereof, wherein said method comprises administering to said patient a therapeutically effective amount of a sigma receptor ligand, wherein a therapeutically effective amount of a microtubule stabilising agent selected from a taxane or a pharmaceutically acceptable derivative thereof has been previously administered to said patient.
48. A method of reducing the toxicity of a microtubule stabilising agent selected from a taxane or a pharmaceutically acceptable derivative thereof, by administering said microtubule stabilising agent in combination with a sigma receptor ligand.
49. A method of delaying the growth of a tumour by administering a microtubule stabilising agent selected from a taxane or a pharmaceutically acceptable derivative thereof, in combination with a sigma receptor ligand.
50. A method of prolonging the life span of a patient with cancer by administrating a microtubule stabilising agent selected from a taxane or a pharmaceutically acceptable derivative thereof, in combination with a sigma receptor ligand.
51. A method of any of claims 45 to 50, wherein said microtubule stabilising agent is paclitaxel (taxol™), docetaxel (taxotere™), DHA-paclitaxel (taxoprexin™), polyglutimate-taxol (OPAXIO™), or a pharmaceutically acceptable derivative thereof.
52. A method of any of claims 45 to 51, wherein said microtubule stabilising agent is paclitaxel (taxol™).
53. A method of any of claims 45 to 52, wherein said sigma receptor ligand is Rimcazole, haloperidol, reduced haloperidol, IPAG (l-(4-iodophenyl)-3-(2-adamantyl)guanidine), DTG (l ,3-di(2-tolyl)guanidine), cis isomers of U50488, or a pharmaceutically acceptable derivative thereof.
54. A method according to any one of claims 45 to 53, wherein said sigma receptor ligand is Rimcazole or a pharmaceutically acceptable derivative thereof.
55. A method according to any one of claims 45 to 54, wherein said sigma receptor ligand is Rimcazole or a pharmaceutically acceptable salt thereof.
56. A method according to any one of claims 45 to 55, wherein said cancer is ovarian, breast, non-small cell lung carcinoma or Kaposi's sarcoma
57. A method according to any one of claims 45 to 56, wherein said cancer is breast cancer.
58. A method of treating breast cancer in a patient in need thereof, wherein said method comprises administering to said patient a therapeutically effective amount of paclitaxel, and a therapeutically effective amount of Rimcazole, wherein said administration is separate, sequential or simultaneous
59. A microtubule stabilising agent, sigma receptor ligand, use, composition, kit, or method of any preceding claim wherein the microtubule stabilising agent and sigma receptor ligand are formulated together for simultaneous administration, wherein said formulation is an intravenous formulation, an intra-peritoneal formulation or an oral formulation.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0907973.2A GB0907973D0 (en) | 2009-05-08 | 2009-05-08 | Combination therapy |
GB0907973.2 | 2009-05-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010128309A1 true WO2010128309A1 (en) | 2010-11-11 |
Family
ID=40833723
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2010/000926 WO2010128309A1 (en) | 2009-05-08 | 2010-05-07 | Combination therapy comprising a taxane and a sigma receptor ligand sauch as rimcazole |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB0907973D0 (en) |
WO (1) | WO2010128309A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017211763A1 (en) * | 2016-06-06 | 2017-12-14 | Laboratorios Del Dr. Esteve, S.A. | Use of sigma receptor ligands in cancer |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0012208A2 (en) | 1978-11-01 | 1980-06-25 | The Wellcome Foundation Limited | 9-(3-(3,5-cis-Dimethylpiperazino)propyl)-carbazole, its preparation and pharmaceutical compositions containing it |
US4924011A (en) | 1988-04-06 | 1990-05-08 | Centre National De La Recherche Scientifique | Process for preparing taxol |
US4924012A (en) | 1988-04-06 | 1990-05-08 | Rhone-Poulenc Sante | Process for preparing derivatives of baccatine III and of 10-deacetyl baccatine III |
US5175315A (en) | 1989-05-31 | 1992-12-29 | Florida State University | Method for preparation of taxol using β-lactam |
US5955459A (en) | 1997-11-26 | 1999-09-21 | Neuromedica, Inc. | Fatty acid-antipsychotic compositions and uses thereof |
WO2000000599A2 (en) | 1998-06-29 | 2000-01-06 | University Of Dundee | Composition for the induction of apoptosis in target cells |
WO2001074359A1 (en) | 2000-03-31 | 2001-10-11 | Barbara Spruce | Sigma receptor ligands and their medical uses |
FR2887454A1 (en) * | 2005-06-28 | 2006-12-29 | Sanofi Aventis Sa | Composition, useful to treat neoplastic diseases, comprises a taxane and a sigma-receptor activator substance |
WO2009103487A1 (en) * | 2008-02-18 | 2009-08-27 | Laboratorios Del Dr. Esteve, S.A. | Use of compounds binding to the sigma receptor ligands for the treatment of neuropathic pain developing as a consequence of chemotherapy |
-
2009
- 2009-05-08 GB GBGB0907973.2A patent/GB0907973D0/en not_active Ceased
-
2010
- 2010-05-07 WO PCT/GB2010/000926 patent/WO2010128309A1/en active Application Filing
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0012208A2 (en) | 1978-11-01 | 1980-06-25 | The Wellcome Foundation Limited | 9-(3-(3,5-cis-Dimethylpiperazino)propyl)-carbazole, its preparation and pharmaceutical compositions containing it |
US4924011A (en) | 1988-04-06 | 1990-05-08 | Centre National De La Recherche Scientifique | Process for preparing taxol |
US4924012A (en) | 1988-04-06 | 1990-05-08 | Rhone-Poulenc Sante | Process for preparing derivatives of baccatine III and of 10-deacetyl baccatine III |
US5175315A (en) | 1989-05-31 | 1992-12-29 | Florida State University | Method for preparation of taxol using β-lactam |
US5955459A (en) | 1997-11-26 | 1999-09-21 | Neuromedica, Inc. | Fatty acid-antipsychotic compositions and uses thereof |
WO2000000599A2 (en) | 1998-06-29 | 2000-01-06 | University Of Dundee | Composition for the induction of apoptosis in target cells |
WO2001074359A1 (en) | 2000-03-31 | 2001-10-11 | Barbara Spruce | Sigma receptor ligands and their medical uses |
FR2887454A1 (en) * | 2005-06-28 | 2006-12-29 | Sanofi Aventis Sa | Composition, useful to treat neoplastic diseases, comprises a taxane and a sigma-receptor activator substance |
WO2009103487A1 (en) * | 2008-02-18 | 2009-08-27 | Laboratorios Del Dr. Esteve, S.A. | Use of compounds binding to the sigma receptor ligands for the treatment of neuropathic pain developing as a consequence of chemotherapy |
Non-Patent Citations (8)
Title |
---|
DOMBERNOWSKY ET AL., SEMINARS IN ONCOLOGY, vol. 22, no. 6, 1995, pages 13 - 17 |
KAYE, SEMINARS IN ONCOLOGY, vol. 22, no. 2, 1995, pages 30 - 33 |
LIANG; CHEN, EXPERT OPINION IN THERAPEUTIC PATENTS, vol. 1 1, no. 6, 2001, pages 981 - 986 |
LIANG; CHEN: "Expert Opinion", THERAPEUTIC PATENTS, vol. 11, no. 6, 2001, pages 981 - 986 |
MALICH G, TOXICOLOGY, vol. 124, no. 3, 1997, pages 179 - 192 |
SHELANSKI ET AL., PNAS, vol. 70, no. 3, 1973, pages 765 |
SPRUCE ET AL., CANCER RESEARCH, vol. 64, 2004, pages 4875 - 4886 |
VILNER ET AL., CANCER RES, vol. 55, no. 2, 1995, pages 408 - 413 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017211763A1 (en) * | 2016-06-06 | 2017-12-14 | Laboratorios Del Dr. Esteve, S.A. | Use of sigma receptor ligands in cancer |
CN109310672A (en) * | 2016-06-06 | 2019-02-05 | 埃斯特韦制药有限公司 | Purposes of the sigma-receptor ligand in cancer |
JP2019517572A (en) * | 2016-06-06 | 2019-06-24 | エスティーブ ファーマシューティカルズ エス エイEsteve Pharmaceuticals, S.A. | Use of sigma receptor ligands in cancer |
CN109310672B (en) * | 2016-06-06 | 2022-05-03 | 埃斯特韦制药有限公司 | Use of sigma receptor ligands in cancer |
JP7094231B2 (en) | 2016-06-06 | 2022-07-01 | エスティーブ ファーマシューティカルズ エス エイ | Use of sigma receptor ligands in cancer |
Also Published As
Publication number | Publication date |
---|---|
GB0907973D0 (en) | 2009-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111886006B (en) | Combination therapy for the treatment of mastocytosis | |
US20160287605A1 (en) | Combination therapy | |
JP6684210B2 (en) | Tyrosine derivative and composition containing the same | |
ES2573715T3 (en) | Sigma ligands for the prevention and / or treatment of vomiting induced by chemotherapy or radiotherapy | |
US20160220574A1 (en) | Nsaid and sigma receptor ligand combinations | |
JP2021514358A (en) | Combination therapy with apirimodo and glutamate | |
KR20140098799A (en) | Combination treatment of cancer | |
CN103052388A (en) | Use of sigma ligands in opioid-induced hyperalgesia | |
EP3253389A1 (en) | Apilimod compositions and methods for using same | |
EP2792352A1 (en) | Alpha-2 adrenoreceptor and sigma receptor ligand combinations | |
JP5514123B2 (en) | Combination drug containing paclitaxel for the treatment of ovarian cancer | |
ES2358931T3 (en) | USE OF A P38 QUINASE INHIBITOR FOR THE TREATMENT OF PSYCHIATRIC DISORDERS. | |
US20230046317A1 (en) | Inhibitors of Glutathione S-Transferases (GSTS) and NAD(P)H:Quinone Oxidoreductase 1 (NQO1), Pharmaceutical Compositions, and Uses in Managing Cancer | |
ES2573295T3 (en) | Pharmaceutical combinations comprising an isoxazole-derived Hsp90 inhibitor and the trastuzumab HER2 inhibitor | |
WO2001008693A2 (en) | Combination therapy using pentafluorobenzenesulfonamide and platin compound | |
WO2010128309A1 (en) | Combination therapy comprising a taxane and a sigma receptor ligand sauch as rimcazole | |
TW202333729A (en) | Combinations | |
TW201902473A (en) | Dosage regimen for TESETAXEL and capecitabine (CAPECITABINE) | |
CA3198547A1 (en) | Rapidly infusing platform and compositions for therapeutic treatment in humans | |
AU2013214731A1 (en) | Compositions comprising NDGA derivatives and sorafenib and their use in treatment of cancer | |
AU2017342262B2 (en) | Apilimod compositions and methods for using same in the treatment of alzheimer's disease | |
CN115427033B (en) | NK-1 receptor antagonists for the treatment of diseases selected from sepsis, septic shock, acute Respiratory Distress Syndrome (ARDS) or Multiple Organ Dysfunction Syndrome (MODS) | |
EP4110326B1 (en) | Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid | |
NZ580482A (en) | Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of motor disorders related to parkinson's disease | |
EP3866782A1 (en) | Methods of treating cns tumors with tesetaxel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10718267 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10718267 Country of ref document: EP Kind code of ref document: A1 |